# cobas® CT/NG Test 510(k) Summary

<table><tr><td rowspan=1 colspan=1>Submitted by:</td><td rowspan=1 colspan=1>Roche Molecular Systems, Inc.4300 Hacienda DrivePleasanton, CA 94588-2722Phone Number: (925) 730-8729Fax Number: (925) 730-8128</td></tr><tr><td rowspan=1 colspan=1>Contact:</td><td rowspan=1 colspan=1>James Bonds</td></tr><tr><td rowspan=1 colspan=1>Date of Preparation:</td><td rowspan=1 colspan=1>January 24, 2012</td></tr><tr><td rowspan=1 colspan=1>Device Trade Name:</td><td rowspan=1 colspan=1>cobas® CT/NG Test</td></tr><tr><td rowspan=1 colspan=1>Common Name:</td><td rowspan=1 colspan=1>Chlamydia trachomatis (CT) and Neisseria gonorrhoea (NG) Test</td></tr><tr><td rowspan=1 colspan=1>Type of Test:</td><td rowspan=1 colspan=1>Nucleic Acid Amplification Test, DNA, Chlamydia trachomatis (CT) andNeisseria gonorrhoea (NG), qualitative</td></tr><tr><td rowspan=1 colspan=1>Classification Names:</td><td rowspan=1 colspan=1>Chlamydia serological reagentsNeisseria spp. Direct serological test reagentsReal Time Nucleic Acid Amplification System</td></tr><tr><td rowspan=1 colspan=1>Regulations:</td><td rowspan=1 colspan=1>866.3120866.3390862.2570</td></tr><tr><td rowspan=1 colspan=1>Product codes:</td><td rowspan=1 colspan=1>MKZ (DNA Probe, Nucleic Acid Amplification, Chlamydia)LSL (DNA Reagents, Neisseria)O0I (Real Time Nucleic Acid Amplification System)</td></tr><tr><td rowspan=1 colspan=1>Panel:</td><td rowspan=1 colspan=1>Microbiology</td></tr><tr><td rowspan=1 colspan=1>Predicate Devices - Assay:</td><td rowspan=1 colspan=1>Gen-Probe APTIMA Combo 2 Assay (K060652)BD ProbeTec Q* Chlamydia trachomatis Amplified DNA Assay (KO91724)and BD ProbeTec Q* Neisseria gonorrhoeae Amplified DNA Assay(K091730)</td></tr><tr><td rowspan=1 colspan=1>Predicate Device - CollectionKits</td><td rowspan=1 colspan=1>Abbott multi-Collect Specimen Collection Kit (K092704)</td></tr></table>

# TABLE OF CONTENTS

1. Device Description. .4   
2. Intended Use... ..5   
3. Technological Characteristics . 5   
4. Non-Clinical Performance Evaluation 8   
4.1. .nalytical tensitivity ..8   
4.2. Inclusivity... ..8   
4.3. Analytical Specificity. .10   
4.4. Interference.... 14   
4.5. Precision... .14   
5. Clinical Performance.. ...15   
5.1. Reproducibility.. ..16   
5.1.1. C. trachomatis (Table 10 and Table 11).. ..16   
5.1.2. N. gonorrhoeae (Table 12 and Table 13) .... ..18   
5.2. Clinical Specimen Study.. ..20   
5.2.1. Study Design.. ..20   
5.2.2. Determination of Patient Infected Status... .21   
5.2.3. Study Results... ..22   
5.2.4. Conclusion Drawn from Clinical Specimen Study. ..28

6. Conclusion.. ..28

# List of Tables

Table 1: Comparison of the cobas® CT/NG Test with the Predicate Devices... ...6   
Table 2: Comparison of the cobas® PCR Sample Collection Devices with the Predicate Device ..7   
Table 3: cobas® CT/NG Test Limit of Detection.. 8   
Table 4: Summary of CT Serovars/Variant Inclusivity Verification Results .. ..9   
Table 5: Summary of NG Strains Inclusivity Verification Results . .10

Table 6: Microorganisms Tested for Analytical Specificity...

TableLis  Microorganisms Teste Below $1 \mathrm { ~ x ~ } 1 0 ^ { 6 }$ copies/ml for Analytical Specificit.13

Table 8: Results from Endogenous Interference Testing... .14

Table 9: In-House Precision Study Hit Rate Analysis... 15

Table 10: C. trachomatis: Percent Agreement by Panel Member for Lot, Site/Instrument, and Day — PCR Media/Urine ... .1€

Table I 1: C. trachomatis: Percent Agreement by Panel Member for Lot, Site/Instrument, and Day - PCR Media/Swab . .18

Table 12: N. gonorrhoeae: Percent Agreement by Panel Member for Lot, Site/Instrument, and Day — PCR Media/Urine . 19

Table 13: N. gonorrhoeae: Percent Agreement by Panel Member for Lot, Site/Instrument, and Day - PCR Media/Swab . .19

Table 14: Determination of Patient Infected Status. .21

Table 15: CT Clinical Performance Compared with Patient Infected Status by Gender, Sample Type, and Symptom Status.. .22

Table 16: NG Clinical Performance Compared With Patient Infected Status by Gender, Sample Type, and Symptom Status... .23

Table 17: CT Positive/Negative Analysis for Female Patient Infected Status .. .25

Table 18: CT Positive/Negative Analysis for Male Patient Infected Status.... ..26

Table 19: NG Positive/Negative Analysis for Female Patient Infected Status... ..26

Table 20: NG Posiive/Negative Analysis for Male Patent Infected Status ..... ..27

Table 21: Positive Predictive Value and Negative Predictive Value for Hypothetical CT Prevalence ...

Table 22: Positive Predictive Value and Negative Predictive Value for Hypothetical NG Prevalence ... .28

# 1. DEVICE DESCRIPTION

The Roche Molecular Systems (RMS) cobas® CT/NG Test consists of five reagent kits:

cobas® 4800 System Sample Preparation Kit cobas® 4800 CT/NG Amplification/Detection Kit cobas® 4800 CT/NG Controls Kit cobas® 4800 System Wash Buffer Kit cobas® 4800 System Control Diluent Kit

Sample Collection Kits to be used for the cobas® CT/NG Test are:

cobas® PCR Female Swab Sample Kit cobas® PCR Urine Sample Kit

The cobas® CT/NG Test for Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) is based on two major processes: (1) automated sample preparation to obtain nucleic acids, including CT and NG DNA; (2) simultaneous PCR amplification of target DNA sequences using both CT and NG specific complementary primer pairs and real-time detection of cleaved fluorescent-labeled CT and NG specific oligonucleotide detection probes. Internal control, containing CT and NG DNA, is added to all samples during automated sample preparation and is amplified and detected simultaneously with each sample to monitor the entire process.

The cobas® 4800 System utilizes the cobas $\yen 480$ Instrument for automated sample preparation, and the automated cobas z 480 Analyzer for automated amplification and detection. The cobas® 4800 system software integrates the sample preparation with nucleic acid amplification and detection to generate test results.

# 2. INTENDED USE

# Assay

The cobas® CT/NG Test is an in vitro nucleic acid amplification test that utilizes Polymerase Chain Reaction (PCR) and nucleic acid hybridization for the qualitative detection of Chlamydia trachomatis (CT) and/or Neisseria gonorrhoeae (NG) DNA to aid in the diagnosis of chlamydial and gonococcal disease. The test may be used with vaginal swab specimens self-collected in a clinical setting and male urine from both symptomatic and asymptomatic individuals. Specimens to be tested should be collected in cobas® PCR Media.

# Ancillary Collection Kits

The cobas® PCR Female Swab Sample Kit is used to collect and transport self-collected vaginal swab specimens in a clinical setting. The cobas® pCR Media serves as a nucleic acid stabilizing transport and storage medium for gynecological specimens. Use this collection kit only with the cobas® CT/NG Test. NOTE: This collection kit should not be used for collection of alternative gynecological specimens.

The cobas® PCR Urine Sample Kit is used to collect and transport male urine specimens. The cobas® PCR Media serves as a nucleic acid stabilizing transport and storage medium for. urine specimens. Use this collection kit only with the cobas® CT/NG Test. NOTE: This collection kit should not be used for collection of female urine specimens.

# 3. TECHNOLOGICAL CHARACTERISTICS

The primary technological characteristics and intended use of the RMS cobas® CT/NG Test are substantially equivalent to other legally marketed nucleic acid amplification tests intended for the qualitative detection of Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG).

As indicated in Table 1, the RMS cobas® CT/NG Test is substantially equivalent to significant characteristics of the identified predicate devices, the Gen-Probe APTIMA Combo 2 Assay (K060652), the BD ProbeTec $\mathsf { Q } ^ { \mathsf { x } }$ Chlamydia trachomatis Amplified DNA Assay (K091724) and the BD ProbeTec $\mathsf { Q } ^ { \boldsymbol { \mathsf { x } } }$ Neisseria gonorrhoeae Amplified DNA Assay (K091730).

Table 1: Comparison of the cobas® CT/NG Test with the Predicate Devices   

<table><tr><td colspan="1" rowspan="1">−</td><td colspan="1" rowspan="1">Submitted Device:RMS cobas® CT/NG Test</td><td colspan="1" rowspan="1">Predicate Device:Gen-Probe APTIMA Combo2 Assay (K060652)</td><td colspan="1" rowspan="1">Predicate Devices:BD ProbeTec Q* CTAmplified DNA Assay(K091724) and BDProbeTec Q* GC AmplifiedDNA Assay (K091730)</td></tr><tr><td colspan="1" rowspan="1">GeneralIntended Use</td><td colspan="1" rowspan="1">Qualitative in vitro diagnostictest for the direct qualitativedetection of Chlamydiatrachomatis and/or Neisseriagonorrhoeae in patientspecimens</td><td colspan="1" rowspan="1">same</td><td colspan="1" rowspan="1">same</td></tr><tr><td colspan="1" rowspan="1">SampleTypes</td><td colspan="1" rowspan="1">Male urinePatient-collected vaginalswabs</td><td colspan="1" rowspan="1">Male urineMale urethral swabsFemale urineEndocervical swabsClinician-collected vaginalswabsPatient-collected vaginalswabsCervical specimens inPreservCyt® media</td><td colspan="1" rowspan="1">Male urineMale urethral swabsFemale urineEndocervical swabsPatient-collected vaginalswabsCervical specimens inPreserCyt® and SurePathmedia</td></tr><tr><td colspan="1" rowspan="1">SubjectStatus</td><td colspan="1" rowspan="1">Asymptomatic andsymptomatic</td><td colspan="1" rowspan="1">Asymptomatic andsymptomatic</td><td colspan="1" rowspan="1">Asymptomatic andsymptomatic</td></tr><tr><td colspan="1" rowspan="1">SampleCollectionDevices</td><td colspan="1" rowspan="1">Urine collection kitSwab collection kit</td><td colspan="1" rowspan="1">Urine collection kitSwab collection kit</td><td colspan="1" rowspan="1">Urine collection kitVaginal collection kit</td></tr><tr><td colspan="1" rowspan="1">CT AnalyteTargets</td><td colspan="1" rowspan="1">CT cryptic plasmid DNACT ompA gene</td><td colspan="1" rowspan="1">CT ribosomal RNA</td><td colspan="1" rowspan="1">CT cryptic plasmid DNA</td></tr><tr><td colspan="1" rowspan="1">NG AnalyteTargets</td><td colspan="1" rowspan="1">NG genomic DNA</td><td colspan="1" rowspan="1">NG ribosomal RNA</td><td colspan="1" rowspan="1">NG genomic DNA</td></tr><tr><td colspan="1" rowspan="1">SamplePreparationProcedure</td><td colspan="1" rowspan="1">Semi-automated</td><td colspan="1" rowspan="1">Semi-automated/automated</td><td colspan="1" rowspan="1">Manual/semi-automated</td></tr><tr><td colspan="1" rowspan="1">AmplificationTechnology</td><td colspan="1" rowspan="1">Real-time PCR</td><td colspan="1" rowspan="1">Ribosomal RNA transcriptionmedicated amplification(TMA)</td><td colspan="1" rowspan="1">Strand displacement DNAamplification (SDA)</td></tr><tr><td colspan="1" rowspan="1">DetectionChemistry</td><td colspan="1" rowspan="1">Paired reporter andquencher fluorescencelabeled probes (TaqManTechnology) usingfluorescence resonanceenergy transfer (FRET)</td><td colspan="1" rowspan="1">Photon measurment fromselectively hybridizedchemiluninescent probesreported as Relative LightUnits (RLU)</td><td colspan="1" rowspan="1">Fluorescent dye labeledprobes using fluorescenceresonance energy transfer(FRET)</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Submitted Device:RMS cobas® CT/NG Test</td><td colspan="1" rowspan="1">Predicate Device:Gen-Probe APTIMA Combo2 Assay (K060652)</td><td colspan="1" rowspan="1">Predicate Devices:BD ProbeTec Q^ CTAmplified DNA Assay(K091724) and BDProbeTec'Q* GC AmplifiedDNA Assay (K091730)</td></tr><tr><td colspan="1" rowspan="1">ResultAnalysis</td><td colspan="1" rowspan="1">Based on PCR cyclethreshold (Ct) analysis</td><td colspan="1" rowspan="1">Determined by a cut-offbased on the total RLU andkinetic curve type</td><td colspan="1" rowspan="1">Determined by relatingMOTA scores (signalstrength) to pre-determinedcutoff values</td></tr></table>

As indicated in Table 2, the cobas® PCR Female Swab Sample Kit and the cobas® PCR Urine Sample Kit are substantially equivalent to those characteristics for the predicate device. The collection kits have the same basic components and intended use, and all are intended as accessories to their respective assays. Data presented in this pre-market notification further support the substantial equivalence of the subject devices to the predicate.

Table 2: Comparison of the cobas® PCR Sample Collection Devices with the Predicate Device   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Submitted Device:RMS cobas® PCR FemaleSwab Sample Kit</td><td rowspan=1 colspan=1>Submitted Device:RMS cobas® PCR UrineSample Kit</td><td rowspan=1 colspan=1>Predicate Device:Abbott multi-CollectSpecimen Collection Kit(K092704)</td></tr><tr><td rowspan=1 colspan=1>GeneralIntended Use</td><td rowspan=1 colspan=1>Collection and transport ofvaginal swab specimensself-collected in a clinicalenvironment for the detectionof Chlamydia trachomatisand Neisseria gonorrhoeaeper the instructions provided.Not intended for home use.</td><td rowspan=1 colspan=1>Collection and transport ofurine specimens for thedetection of Chlamydiatrachomatis and Neisseriagonorrhoeae per theinstructions provided. Notintended for home use.</td><td rowspan=1 colspan=1>Collection and transport ofmale and female, swab andurine specimens for thedetection of Chlamydiatrachomatis and Neisseriagonorrhoeae per instructionsprovided. Not intended forhome use.</td></tr><tr><td rowspan=1 colspan=1>SampleTypes</td><td rowspan=1 colspan=1>Vaginal swab self-collectedin a clinical setting</td><td rowspan=1 colspan=1>Male urine</td><td rowspan=1 colspan=1>Male urineMale urethral swabsFemale urineEndocervical swabsVaginal swabs, cliniciancollected and self-collected</td></tr></table>

In summary, the intended use, technology, and functionality of the cobas® CT/NG Test as compared to the predicate devices do not raise any new types of safety or effectiveness questions and are substantially equivalent.

# 4. NON-CLINICAL PERFORMANCE EVALUATION

# 4.1 Analytical Sensitivity

The analytical sensitivity (Limit of Detection or LOD) for the cobas® CT/NG Test was determined by analyzing dilutions of quantified CT and NG cultures. Cultures of CT and NG were diluted into negative vaginal swab specimen in cobas® pCR Media and negative urine specimen plus cobas® PCR Media to determine the LOD for vaginal swab and urine specimens, respectively. All levels were analyzed using the full cobas® CT/NG Test workflow across 3 unique lots of cobas® CT/NG Test reagents. This test defines LOD as the target concentration which can be detected as positive in $\ge 9 5 \%$ of the replicates tested with each reagent lot.

The LOD for the CT serovar D culture and NG strain 19424 in cobas® PCR Media, vaginal swab specimens stabilized in cobas® PCR Media and urine specimens diluted into cobas® PCR Media are shown in Table 3.

Table 3: cobas® CT/NG Test Limit of Detection   

<table><tr><td rowspan=2 colspan=1>Specimen Types</td><td rowspan=1 colspan=3>C. trachomatis</td><td rowspan=1 colspan=3>N. gonorrhoeae</td></tr><tr><td rowspan=1 colspan=1>LevelsTested</td><td rowspan=1 colspan=1>Replicates/Level</td><td rowspan=1 colspan=1>LOD(IFU/mL)</td><td rowspan=1 colspan=1>LevelsTested</td><td rowspan=1 colspan=1>Replicates/Level</td><td rowspan=1 colspan=1>LOD(CFU/mL)</td></tr><tr><td rowspan=1 colspan=1>Urine</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>192*</td><td rowspan=1 colspan=1>0.75</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>192*</td><td rowspan=1 colspan=1>2.25</td></tr><tr><td rowspan=1 colspan=1>Vaginal Swabs</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>192**</td><td rowspan=1 colspan=1>10.00</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>192**</td><td rowspan=1 colspan=1>100.00</td></tr></table>

\*Testing included one negative level with 167-168 replicates \*\*Testing included one negative level with 82-84 replicates

# 4.2. Inclusivity

The sensitivity of the cobas® CT/NG Test was determined for 14 additional CT serovars, the Swedish new variant (nvCT) strain and an additional 44 independently isolated strains of NG. Testing was done to demonstrate that these targets can be detected around the LOD levels determined during analytical sensitivity testing for the CT serovar D culture and NG strain

19424. Panels were prepared as described for the LOD study with the number of panel levels varying from 1 to 5, as required. At least 49 replicates were tested for each panel level using one lot of cobas®CT/NG Test reagents. Results are shown in Table 4 and Table 5. In Table 5, all NG strains with identical LOD results are presented as a group, shown in the columns labeled Numbers of NG Strains." Since LOD evaluation was done with samples stabilized in cobas® PCR Media, the LOD for untreated urine is twice the level reported in Table 4 and Table 5.

The analytical sensitivity for all 14 CT serovars plus the nvCT variant (Table 4) ranged from 0.2 IFU/mL ( $\mathrm { { I F U = } }$ Inclusion Forming Units) to $5 . 0 \ \mathrm { I F U / m L }$ in cobas® PCR Media and from 0.13 IFU/mL to $0 . 7 5 \mathrm { ~ I F U / m L }$ in cobas® PCR Media plus negative urine specimen. All CT serovars and the nvCT variant were tested at 10 IFU/mL only in stabilized negative vaginal specimen and all showed $100 \%$ positive hit rates at $1 0 ~ \mathrm { I F U / m L }$ .

The analytical sensitivity for all $4 4 ~ \mathrm { N G }$ strains ranged from 3.0 CFU/mL to 20 CFU/mL in cobas® PCR Media and was $3 . 7 5 \mathrm { C F U / m L }$ in cobas® PCR Media plus urine specimens. All NG strains were tested at $1 0 0 \mathrm { C F U / m L }$ only in stabilized negative vaginal specimen. All showed $1 0 0 \%$ hit rates at $1 0 0 \ : \mathrm { C F U / m L }$ $\mathrm { C F U } =$ Colony Forming Units).

Table 4: Summary of CT Serovars/Variant Inclusivity Verification Results   

<table><tr><td colspan="1" rowspan="3">Serovar Type orVariant</td><td colspan="4" rowspan="1">LOD Results for C. trachomatis</td></tr><tr><td colspan="2" rowspan="1">Vaginal Swabs*</td><td colspan="2" rowspan="1">Urine</td></tr><tr><td colspan="1" rowspan="1">IFU/mL</td><td colspan="1" rowspan="1">% POs</td><td colspan="1" rowspan="1">IFU/mL</td><td colspan="1" rowspan="1">% Pos</td></tr><tr><td colspan="1" rowspan="1">A</td><td colspan="1" rowspan="1">10.0</td><td colspan="1" rowspan="1">100%</td><td colspan="1" rowspan="1">0.125</td><td colspan="1" rowspan="1">98%</td></tr><tr><td colspan="1" rowspan="1">B</td><td colspan="1" rowspan="1">10.0</td><td colspan="1" rowspan="1">100%</td><td colspan="1" rowspan="1">0.75</td><td colspan="1" rowspan="1">100%</td></tr><tr><td colspan="1" rowspan="1">Ba</td><td colspan="1" rowspan="1">10.0</td><td colspan="1" rowspan="1">100%</td><td colspan="1" rowspan="1">0.75</td><td colspan="1" rowspan="1">100%</td></tr><tr><td colspan="1" rowspan="1">C</td><td colspan="1" rowspan="1">10.0</td><td colspan="1" rowspan="1">100%</td><td colspan="1" rowspan="1">0.75</td><td colspan="1" rowspan="1">100%</td></tr><tr><td colspan="1" rowspan="1">E</td><td colspan="1" rowspan="1">10.0</td><td colspan="1" rowspan="1">100%</td><td colspan="1" rowspan="1">0.75</td><td colspan="1" rowspan="1">100%</td></tr><tr><td colspan="1" rowspan="1">F</td><td colspan="1" rowspan="1">10.0</td><td colspan="1" rowspan="1">100%</td><td colspan="1" rowspan="1">0.75</td><td colspan="1" rowspan="1">100%</td></tr><tr><td colspan="1" rowspan="1">G</td><td colspan="1" rowspan="1">10.0</td><td colspan="1" rowspan="1">100%</td><td colspan="1" rowspan="1">0.75</td><td colspan="1" rowspan="1">100%</td></tr><tr><td colspan="1" rowspan="1">H</td><td colspan="1" rowspan="1">10.0</td><td colspan="1" rowspan="1">100%</td><td colspan="1" rowspan="1">0.75</td><td colspan="1" rowspan="1">100%</td></tr><tr><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">10.0</td><td colspan="1" rowspan="1">100%</td><td colspan="1" rowspan="1">0.75</td><td colspan="1" rowspan="1">98%</td></tr><tr><td colspan="1" rowspan="1">J</td><td colspan="1" rowspan="1">10.0</td><td colspan="1" rowspan="1">100%</td><td colspan="1" rowspan="1">0.125</td><td colspan="1" rowspan="1">96%</td></tr><tr><td colspan="1" rowspan="1">K</td><td colspan="1" rowspan="1">10.0</td><td colspan="1" rowspan="1">100%</td><td colspan="1" rowspan="1">0.75</td><td colspan="1" rowspan="1">100%</td></tr><tr><td colspan="1" rowspan="1">LV Type 1</td><td colspan="1" rowspan="1">10.0</td><td colspan="1" rowspan="1">100%</td><td colspan="1" rowspan="1">0.125</td><td colspan="1" rowspan="1">100%</td></tr><tr><td colspan="1" rowspan="1">LV Type 2</td><td colspan="1" rowspan="1">10.0</td><td colspan="1" rowspan="1">100%</td><td colspan="1" rowspan="1">0.125</td><td colspan="1" rowspan="1">100%</td></tr><tr><td colspan="1" rowspan="1">LV Type 3</td><td colspan="1" rowspan="1">10.0</td><td colspan="1" rowspan="1">100%</td><td colspan="1" rowspan="1">0.125</td><td colspan="1" rowspan="1">100%</td></tr><tr><td colspan="1" rowspan="1">nvCT</td><td colspan="1" rowspan="1">10.0</td><td colspan="1" rowspan="1">100%</td><td colspan="1" rowspan="1">0.75</td><td colspan="1" rowspan="1">100%</td></tr></table>

Table 5: Summary of NG Strains Inclusivity Verification Results   

<table><tr><td rowspan=2 colspan=1>Numbers of NGStrains</td><td rowspan=1 colspan=2>LOD Urine</td></tr><tr><td rowspan=1 colspan=1>CFU/mL</td><td rowspan=1 colspan=1>% Hit Rate</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>3.75</td><td rowspan=1 colspan=1>96%</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>3.75</td><td rowspan=1 colspan=1>98%</td></tr><tr><td rowspan=1 colspan=1>37</td><td rowspan=1 colspan=1>3.75</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>Total = 44</td><td rowspan=1 colspan=2></td></tr><tr><td rowspan=1 colspan=3></td></tr><tr><td rowspan=2 colspan=1>Numbers of NGStrains</td><td rowspan=1 colspan=2>LOD Vaginal Swabs*</td></tr><tr><td rowspan=1 colspan=1>CFU/mL</td><td rowspan=1 colspan=1>% Hit Rate</td></tr><tr><td rowspan=1 colspan=1>Total = 44</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>100%</td></tr></table>

# . Competitive Inhibition

Panels were prepared by spiking CT and NG cultures into urine and vaginal specimens stabilized in cobas® pCR Media to various concentration levels to examine the potential for competitive inhibition. Panels were prepared with two strains each of CT and NG. Panels were tested in one run per day over the course of 5 days. Two replicates of each panel member were tested in every run, generating a maximum of 10 test results for each level and CT and NG strain respectively. Average Ct values for each of the panel levels are summarized in Tables 6 and 7. All CT and NG hit rates were $100 \%$ for all panel levels in both matrices. Competitive inhibition was not seen in any combination of CT and NG levels in either matrix.

Table 6: Competitive inhibition Study for CT and NG Cultures in Urine Stabilized in cobas® PCR Media (Ct Values)   

<table><tr><td colspan="2" rowspan="1">Panel Level</td><td colspan="2" rowspan="1">Strain 1</td><td colspan="2" rowspan="1">Strain 2</td></tr><tr><td colspan="1" rowspan="1">CT Level/1FU/mL</td><td colspan="1" rowspan="1">NG Level /(CFU/mL)</td><td colspan="1" rowspan="1">CT</td><td colspan="1" rowspan="1">NG</td><td colspan="1" rowspan="1">CT</td><td colspan="1" rowspan="1">NG</td></tr><tr><td colspan="1" rowspan="1">Low/2</td><td colspan="1" rowspan="1">Low/6</td><td colspan="1" rowspan="1">35.1</td><td colspan="1" rowspan="1">34.8</td><td colspan="1" rowspan="1">32.5</td><td colspan="1" rowspan="1">34.8</td></tr><tr><td colspan="1" rowspan="1">Low/2</td><td colspan="1" rowspan="1">Medium/24</td><td colspan="1" rowspan="1">34.9</td><td colspan="1" rowspan="1">33.1</td><td colspan="1" rowspan="1">32.6</td><td colspan="1" rowspan="1">33.0</td></tr><tr><td colspan="1" rowspan="1">Medium/8</td><td colspan="1" rowspan="1">Low/6</td><td colspan="1" rowspan="1">33.5</td><td colspan="1" rowspan="1">34.1</td><td colspan="1" rowspan="1">30.1</td><td colspan="1" rowspan="1">35.0</td></tr><tr><td colspan="1" rowspan="1">High/1.00E+05</td><td colspan="1" rowspan="1">Low/6</td><td colspan="1" rowspan="1">19.4</td><td colspan="1" rowspan="1">34.1</td><td colspan="1" rowspan="1">18.6</td><td colspan="1" rowspan="1">35.0</td></tr><tr><td colspan="1" rowspan="1">Low/2</td><td colspan="1" rowspan="1">High/1.00E+06</td><td colspan="1" rowspan="1">35.2</td><td colspan="1" rowspan="1">17.6</td><td colspan="1" rowspan="1">32.6</td><td colspan="1" rowspan="1">17.4</td></tr><tr><td colspan="1" rowspan="1">High/1.00E+05</td><td colspan="1" rowspan="1">High/1.00E+06</td><td colspan="1" rowspan="1">19.5</td><td colspan="1" rowspan="1">18.1</td><td colspan="1" rowspan="1">18.9</td><td colspan="1" rowspan="1">17.7</td></tr></table>

Table 7: Competitive inhibition Study for CT and NG Cultures in Vaginal Swabs Collected in cobas® PCR Media (Ct Values)   

<table><tr><td rowspan=1 colspan=2>Panel Level</td><td rowspan=1 colspan=2>Strain 1</td><td rowspan=1 colspan=2>Strain 2</td></tr><tr><td rowspan=1 colspan=1>CT Level/IFU/mL</td><td rowspan=1 colspan=1>NG Level /(CFU/mL)</td><td rowspan=1 colspan=1>CT</td><td rowspan=1 colspan=1>NG</td><td rowspan=1 colspan=1>CT</td><td rowspan=1 colspan=1>NG</td></tr><tr><td rowspan=1 colspan=1>Low/25</td><td rowspan=1 colspan=1>Low/250</td><td rowspan=1 colspan=1>36.4</td><td rowspan=1 colspan=1>35.1</td><td rowspan=1 colspan=1>34.1</td><td rowspan=1 colspan=1>34.7</td></tr><tr><td rowspan=1 colspan=1>Low/25</td><td rowspan=1 colspan=1>Medium/1000</td><td rowspan=1 colspan=1>36.2</td><td rowspan=1 colspan=1>33.2</td><td rowspan=1 colspan=1>33.7</td><td rowspan=1 colspan=1>31.8</td></tr><tr><td rowspan=1 colspan=1>Medium/100</td><td rowspan=1 colspan=1>Low/250</td><td rowspan=1 colspan=1>34.5</td><td rowspan=1 colspan=1>35.1</td><td rowspan=1 colspan=1>32.2</td><td rowspan=1 colspan=1>34.4</td></tr><tr><td rowspan=1 colspan=1>High/1.00E+05</td><td rowspan=1 colspan=1>Low/250</td><td rowspan=1 colspan=1>23.9</td><td rowspan=1 colspan=1>33.8</td><td rowspan=1 colspan=1>22.9</td><td rowspan=1 colspan=1>33.8</td></tr><tr><td rowspan=1 colspan=1>Low/25</td><td rowspan=1 colspan=1>High/1.00E+06</td><td rowspan=1 colspan=1>35.7</td><td rowspan=1 colspan=1>22.8</td><td rowspan=1 colspan=1>33.8</td><td rowspan=1 colspan=1>22.0</td></tr><tr><td rowspan=1 colspan=1>High/1.00E+05</td><td rowspan=1 colspan=1>High/1.00E+06</td><td rowspan=1 colspan=1>23.7</td><td rowspan=1 colspan=1>23.2</td><td rowspan=1 colspan=1>21.9</td><td rowspan=1 colspan=1>22.1</td></tr></table>

# 4.4. Analytical Specificity

A panel of 184 bacteria, fungi and viruses, including those commonly found in the male/female urogenital tract, as well as representatives of N. cineria, N. flava, N. lactamica, N. perflava and N. subflava and other phylogenetically related organisms, were tested with the cobas® CT/NG Test to assess analytical specificity. The organisms listed in Table 6 were spiked at high concentrations (microorganisms tested below ${ \mathrm { ~ l ~ x ~ l 0 } } ^ { 6 }$ copies/mL are listed in Table 9) into CT/NG negative urine specimens plus cobas® pCR Media and pooled negative vaginal specimen spiked with CT and NG cultures at 3 times the limit of detection.

Results indicated that none of these organisms interfered with detection of CT and NG or produced a false positive result in the CT/NG negative matrices.

Table 8: Microorganisms Tested for Analytical Specificity   

<table><tr><td colspan="1" rowspan="1">Achromobacter xerosis</td><td colspan="1" rowspan="1">Helicobacter pylori</td><td colspan="1" rowspan="1">Neisseria sicca</td></tr><tr><td colspan="1" rowspan="1">Acinetobacter calcoaceticus</td><td colspan="1" rowspan="1">Hepatitis B virus (HBV)</td><td colspan="1" rowspan="1">Neisseria subflava</td></tr><tr><td colspan="1" rowspan="1">Acinetobacter Iwoffi</td><td colspan="1" rowspan="1">Hepatitis C virus (HCV)</td><td colspan="1" rowspan="1">Neisseria subflava 6458</td></tr><tr><td colspan="1" rowspan="1">Acinetobacter sp. genospecies 3</td><td colspan="1" rowspan="1">Human immunodeficiency virus</td><td colspan="1" rowspan="1">Neisseria subfiava 6617</td></tr><tr><td colspan="1" rowspan="1">Actinomyces israelii</td><td colspan="1" rowspan="1">Human papillomavirus type 16(CaSki cells)</td><td colspan="1" rowspan="1">Neisseria subflava 6618</td></tr><tr><td colspan="1" rowspan="1">Actinomyces pyogenes</td><td colspan="1" rowspan="1">Human papillomavirus type 18(HeLa cells)</td><td colspan="1" rowspan="1">Neisseria subflava 7441</td></tr><tr><td colspan="1" rowspan="1">Adenovirus</td><td colspan="1" rowspan="1">Herpes Simplex Virus (HSV-1)</td><td colspan="1" rowspan="1">Neisseria subflava 7452</td></tr><tr><td colspan="1" rowspan="1">Aerococcus vinidans</td><td colspan="1" rowspan="1">Herpes Simplex Virus (HSV-2)</td><td colspan="1" rowspan="1">Neisseria weaveri</td></tr><tr><td colspan="1" rowspan="1">Aeromonas hydrophila</td><td colspan="1" rowspan="1">Kingella dentrificans</td><td colspan="1" rowspan="1">Pantoea aggiomerans</td></tr><tr><td colspan="1" rowspan="1">Alcaligenes faecalis</td><td colspan="1" rowspan="1">Kingella kingae</td><td colspan="1" rowspan="1">Paracoccus denitrificans</td></tr><tr><td colspan="1" rowspan="1">Bacillus subtilis</td><td colspan="1" rowspan="1">Klebsiella oxytoca</td><td colspan="1" rowspan="1">Pasteurella maltocida</td></tr><tr><td colspan="1" rowspan="1">Bacillus thuringiensis</td><td colspan="1" rowspan="1">Klebsiella pneumoniae ss ozaenae</td><td colspan="1" rowspan="1">Pediococcus acidilactica</td></tr><tr><td colspan="1" rowspan="1">Bacteroides caccae</td><td colspan="1" rowspan="1">Lactobacillus acidophillus</td><td colspan="1" rowspan="1">Peptostreptococcus anaerobius</td></tr><tr><td colspan="1" rowspan="1">Bacteroides fragilis</td><td colspan="1" rowspan="1">Lactobacillus brevis</td><td colspan="1" rowspan="1">Peptostreptococcus asacharolyticus</td></tr><tr><td colspan="1" rowspan="1">Bacteroides ureolyticus</td><td colspan="1" rowspan="1">Lactobacillus crispatus</td><td colspan="1" rowspan="1">Peptostreptococcus magnus</td></tr><tr><td colspan="1" rowspan="1">Bifidobacterium adolescentis</td><td colspan="1" rowspan="1">Lactobacillus delbruecki subsp.lactis</td><td colspan="1" rowspan="1">Plesiomonas shigelloides</td></tr><tr><td colspan="1" rowspan="1">Bifidobacterium breve</td><td colspan="1" rowspan="1">Lactobacillus jensenii</td><td colspan="1" rowspan="1">Prevotella bivia</td></tr><tr><td colspan="1" rowspan="1">Bifidobacterium longum</td><td colspan="1" rowspan="1">Lactobacillus lactis lactis</td><td colspan="1" rowspan="1">Prevotella corporis</td></tr><tr><td colspan="1" rowspan="1">Branhamella catarrhalis</td><td colspan="1" rowspan="1">Lactobacillus oris</td><td colspan="1" rowspan="1">Prevotella intermedia</td></tr><tr><td colspan="1" rowspan="1">Brevibacterium linens</td><td colspan="1" rowspan="1">Lactobacillus parabuchnemi</td><td colspan="1" rowspan="1">Propionibacterium acnes</td></tr><tr><td colspan="1" rowspan="1">Campylobacter gracilis</td><td colspan="1" rowspan="1">Lactobacillus vaginalis</td><td colspan="1" rowspan="1">Proteus mirabilis</td></tr><tr><td colspan="1" rowspan="1">Campylobacter jejuni</td><td colspan="1" rowspan="1">Lactococcus lactis cremoris</td><td colspan="1" rowspan="1">Proteus vulganis</td></tr><tr><td colspan="1" rowspan="1">Candida albicans</td><td colspan="1" rowspan="1">Legionella bozemnii</td><td colspan="1" rowspan="1">Providencia stuartii</td></tr><tr><td colspan="1" rowspan="1">Candida glabrata</td><td colspan="1" rowspan="1">Legionella pneumophila</td><td colspan="1" rowspan="1">Pseudomonas aeruginosa</td></tr><tr><td colspan="1" rowspan="1">Candida guilliermondi</td><td colspan="1" rowspan="1">Listeria monocytogenes</td><td colspan="1" rowspan="1">Pseudomonas fluorescens</td></tr><tr><td colspan="1" rowspan="1">Candida krusei</td><td colspan="1" rowspan="1">Micrococcus luteus</td><td colspan="1" rowspan="1">Pseudomonas putida</td></tr><tr><td colspan="1" rowspan="1">Candida parapsilosis</td><td colspan="1" rowspan="1">Miluncus crtisi subsp.rs</td><td colspan="1" rowspan="1">Rahnella aquatilis</td></tr><tr><td colspan="1" rowspan="1">Candida tropicalis</td><td colspan="1" rowspan="1">Mobiluncus curtisii subsp. holmesi</td><td colspan="1" rowspan="1">Rhizobium radiobacter</td></tr><tr><td colspan="1" rowspan="1">Chlamydophila pneumoniae</td><td colspan="1" rowspan="1">Mobiluncus mulieris</td><td colspan="1" rowspan="1">Rhodospirillum rubrum</td></tr><tr><td colspan="1" rowspan="1">Chromobacter violaceum</td><td colspan="1" rowspan="1">Moraxella catarrhalis</td><td colspan="1" rowspan="1">Ruminococcus productus</td></tr><tr><td colspan="1" rowspan="1">Chryseobacteriummeningosepticum</td><td colspan="1" rowspan="1">Moraxella lacunata</td><td colspan="1" rowspan="1">Saccharomyces cerevisiae</td></tr><tr><td colspan="1" rowspan="1">Citrobacter braakii</td><td colspan="1" rowspan="1">Moraxella osloensis</td><td colspan="1" rowspan="1">Salmonella Choleraesuis</td></tr><tr><td colspan="1" rowspan="1">Citrobacter freundii</td><td colspan="1" rowspan="1">Morganella morganii</td><td colspan="1" rowspan="1">Salmonella Minnesota</td></tr><tr><td colspan="1" rowspan="1">Clostridium innocuum</td><td colspan="1" rowspan="1">Mycobacterium avium</td><td colspan="1" rowspan="1">Salmonella Typhimurium</td></tr><tr><td colspan="1" rowspan="1">Clostridium perfringens</td><td colspan="1" rowspan="1">Mycobacterium gordonae</td><td colspan="1" rowspan="1">Serratia denitrificans</td></tr><tr><td colspan="1" rowspan="1">Clostridium sporogenes</td><td colspan="1" rowspan="1">Mycobacterium smegmatis</td><td colspan="1" rowspan="1">Serratia marcescens</td></tr><tr><td colspan="1" rowspan="1">Corynebacterium genitalium</td><td colspan="1" rowspan="1">Mycoplasma genitalium</td><td colspan="1" rowspan="1">Staphylococcus aureus</td></tr><tr><td colspan="1" rowspan="1">Corynebacterium renale</td><td colspan="1" rowspan="1">Mycoplasma hominis</td><td colspan="1" rowspan="1">Staphylococcus epidermidis</td></tr><tr><td colspan="1" rowspan="1">Corynebacterium xerosis</td><td colspan="1" rowspan="1">Mycoplasma pneumoniae</td><td colspan="1" rowspan="1">Staphylococcus saprophyticus</td></tr><tr><td colspan="1" rowspan="1">Cryptococcus neoformans</td><td colspan="1" rowspan="1">Neisseria cinerea 832</td><td colspan="1" rowspan="1">Streptococcus agalactiae</td></tr><tr><td colspan="1" rowspan="1">Cytomegalovirus</td><td colspan="1" rowspan="1">Neisseria cinerea 3306</td><td colspan="1" rowspan="1">Streptococcus anginosus</td></tr><tr><td colspan="1" rowspan="1">Deinococcus radiodurans</td><td colspan="1" rowspan="1">Neisseria cinerea 3307</td><td colspan="1" rowspan="1">Streptococcus bovis</td></tr><tr><td colspan="1" rowspan="1">Deinococcus radiopugnans</td><td colspan="1" rowspan="1">Neisseria cinerea 3308</td><td colspan="1" rowspan="1">Streptococcus dysgalactiae</td></tr></table>

Table 9: List of Microorganisms Tested Below $\mathbf { 1 \ x \ 1 0 ^ { 6 } }$ copies/mL for Analytical Specficity   

<table><tr><td rowspan=1 colspan=1>Derxia gummosa</td><td rowspan=1 colspan=1>Neisseria cinerea 6317</td><td rowspan=1 colspan=1>Streptococcus equinis</td></tr><tr><td rowspan=1 colspan=1>Edwardsiella tarda</td><td rowspan=1 colspan=1>Neisseria dentrificans</td><td rowspan=1 colspan=1>Streptococcus mitis</td></tr><tr><td rowspan=1 colspan=1>Eikenella corrodens</td><td rowspan=1 colspan=1>Neisseria elongata ssp.nitroreducans</td><td rowspan=1 colspan=1>Streptococcus mutans</td></tr><tr><td rowspan=1 colspan=1>Enterobacter aerogenes</td><td rowspan=1 colspan=1>Neisseria flava</td><td rowspan=1 colspan=1>Streptococcus pneumoniae</td></tr><tr><td rowspan=1 colspan=1>Enterobacter cloacae</td><td rowspan=1 colspan=1>Neisseria flavescens</td><td rowspan=1 colspan=1>Streptococcus pyogenes</td></tr><tr><td rowspan=1 colspan=1>Enterococcus avium</td><td rowspan=1 colspan=1>Neisseria kochi</td><td rowspan=1 colspan=1>Streptococcus salivarius</td></tr><tr><td rowspan=1 colspan=1>Enterococcus faecalis</td><td rowspan=1 colspan=1>Neisseria lactamica</td><td rowspan=1 colspan=1>Streptococcus sanguis</td></tr><tr><td rowspan=1 colspan=1>Enterococcus faecium</td><td rowspan=1 colspan=1>Neisseria meningitidis 135</td><td rowspan=1 colspan=1>Streptomyces griseinus</td></tr><tr><td rowspan=1 colspan=1>Epstein Barr Virus</td><td rowspan=1 colspan=1>Neisseria meningitidis Serogroup A</td><td rowspan=1 colspan=1>Treponema pallidum</td></tr><tr><td rowspan=1 colspan=1>Erwinia herbicola</td><td rowspan=1 colspan=1>Neisseria meningitidis Serogroup B</td><td rowspan=1 colspan=1>Trichomonas vaginalis</td></tr><tr><td rowspan=1 colspan=1>Erysipelothrix usiopathiae</td><td rowspan=1 colspan=1>Neisseria meningitidis Serogroup C</td><td rowspan=1 colspan=1>Ureaplasma urealyticum</td></tr><tr><td rowspan=1 colspan=1>Escherichia coli</td><td rowspan=1 colspan=1>Neisseria meningitidis Serogroup D</td><td rowspan=1 colspan=1>Veillonela parvula</td></tr><tr><td rowspan=1 colspan=1>Ewingella americana</td><td rowspan=1 colspan=1>Neisseria meningitidis Serogroup Y</td><td rowspan=1 colspan=1>Vibrio parahaemolyticus</td></tr><tr><td rowspan=1 colspan=1>Flavobacterium meningosepticum</td><td rowspan=1 colspan=1>Neisseria mucosa</td><td rowspan=1 colspan=1>Weissella paramesenteroides</td></tr><tr><td rowspan=1 colspan=1>Fusobacterium nucleatum</td><td rowspan=1 colspan=1>Neisseria perflava 837</td><td rowspan=1 colspan=1>Yersinia enterocolitica</td></tr><tr><td rowspan=1 colspan=1>Gardnerella vaginalis</td><td rowspan=1 colspan=1>Neisseria perflava 911</td><td rowspan=5 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Gemella haemolysans</td><td rowspan=1 colspan=1>Neisseria perflava 6339</td></tr><tr><td rowspan=1 colspan=1>Gemella morbillorum</td><td rowspan=1 colspan=1>Neisseria perflava 6340</td></tr><tr><td rowspan=1 colspan=1>Haemophilus ducreyi</td><td rowspan=1 colspan=1>Neisseria perflava 6341</td></tr><tr><td rowspan=1 colspan=1>Haemophilus influenzae</td><td rowspan=1 colspan=1>Neisseria polysaccharea</td></tr></table>

<table><tr><td rowspan=2 colspan=1>Microorganism Tested</td><td rowspan=1 colspan=2>Concentration Tested in Listed Matrix*</td></tr><tr><td rowspan=1 colspan=1>Negative UrineSpecimen pluscoobasPCR Media</td><td rowspan=1 colspan=1>Negative VaginalSpecimen pluscobasPCR Media</td></tr><tr><td rowspan=1 colspan=1>Adenovirus</td><td rowspan=1 colspan=1>8x103 copies/mL</td><td rowspan=1 colspan=1>8x103 copies/mL</td></tr><tr><td rowspan=1 colspan=1>Chlamydophila pneumoniae</td><td rowspan=1 colspan=1>1.1x104 copies/mL</td><td rowspan=1 colspan=1>1.1x104 copies/mL</td></tr><tr><td rowspan=1 colspan=1>Gemella morbillorum</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>4.5 x 104 copies/mL</td></tr><tr><td rowspan=1 colspan=1>Hepatitis C virus (HCV)</td><td rowspan=1 colspan=1>5.6 x 104 copies/mL</td><td rowspan=1 colspan=1>5.6 x 104 copies/mL</td></tr><tr><td rowspan=1 colspan=1>Human papillomavirus (HPV) type 16(SiHa cells)</td><td rowspan=1 colspan=1>5x104 copies/miL</td><td rowspan=1 colspan=1>5x104 copies/mL</td></tr><tr><td rowspan=1 colspan=1>Human papillomavirus (HPV) type 18(HeLa cells)</td><td rowspan=1 colspan=1>1x104 copies/mL</td><td rowspan=1 colspan=1>1x104 copies/mL</td></tr><tr><td rowspan=1 colspan=1>Neisseria cinerea 3308</td><td rowspan=1 colspan=1>4x10 copies/mL</td><td rowspan=1 colspan=1>4x10^ copies/mL</td></tr><tr><td rowspan=1 colspan=1>Prevotella bivia</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>9x104 copies/mL</td></tr><tr><td rowspan=1 colspan=1>Prevotella corporis</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>1.4x103 copies/mL</td></tr><tr><td rowspan=1 colspan=1>Treponema pallidum</td><td rowspan=1 colspan=1>Not Tested</td><td rowspan=1 colspan=1>1x103 copies/mL</td></tr><tr><td rowspan=1 colspan=1>Trichomonas vaginalis</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>6.5x105 copies/mL</td></tr></table>

# \*Gray cells indicate concentration tested was ≥ 1 x 106 copies/mL in that matrix

# 4.5. Interference

Interference testing was performed using cobas® pCR Media plus negative urine and negative vaginal swab specimen spiked with CT and NG cultures at $\sim 3 \ : \mathbf { x }$ LOD for each target. Eighteen over-the-counter (OTC) products, including contraceptive jelly, lubricants, feminine sprays, antifungal cream and anti-itch cream, as well as whole blood, cervical mucus and PBMC cells were tested for interference. Of the 18 OTC products tested, Replens® vaginal moisturizer produced invalid and/or false negative results in the cobas® pCR Media plus negative urine panel samples. No interference from Replens® vaginal moisturizer was observed with vaginal swab specimens tested.

The levels of whole blood, mucus and PBMC cells shown in Table 10 represent maximum allowable concentrations which will not interfere with cobas® CT/NG Test performance. Concentrations in urine samples were determined using total sample volume, including stabilizing media.

Table 10: Results from Endogenous Interference Testing   

<table><tr><td rowspan=2 colspan=1></td><td rowspan=1 colspan=2>Blood (v/v)</td><td rowspan=1 colspan=2>PBMC (cells/mL)</td><td rowspan=1 colspan=2>Mucus</td></tr><tr><td rowspan=1 colspan=1>Conc.Tested</td><td rowspan=1 colspan=1>InterferenceObserved</td><td rowspan=1 colspan=1>Conc.Tested</td><td rowspan=1 colspan=1>InterferenceObserved</td><td rowspan=1 colspan=1>Conc.Tested</td><td rowspan=1 colspan=1>InterferenceObserved</td></tr><tr><td rowspan=1 colspan=1>Urine stabilized incobas® PCR Media</td><td rowspan=1 colspan=1>0, 0.25%,0.35%, 0.5%,1%, 3%</td><td rowspan=1 colspan=1>&gt; 0.35%</td><td rowspan=1 colspan=1>0, 1.0E+05,1.0E+06,1.0E+07</td><td rowspan=1 colspan=1>&gt; 1x 10fr}$</td><td rowspan=1 colspan=1>NT</td><td rowspan=1 colspan=1>NT</td></tr><tr><td rowspan=1 colspan=1>Vaginal Specimenstabilized in cobas® PCRMeia</td><td rowspan=1 colspan=1>0,1%,3%, 5%, 10%</td><td rowspan=1 colspan=1>None</td><td rowspan=1 colspan=1>0.1.0E+05,1.0E+06,1.0E+07</td><td rowspan=1 colspan=1>&gt;1x 105}$</td><td rowspan=1 colspan=1>Routinelevel*</td><td rowspan=1 colspan=1>None</td></tr></table>

NT $\equiv$ Not Tested \*Routine level $=$ Quantiy eril ucus uivalent t ormally ov rr  spl

# 4.6. Precision

Precision of the cobas® CT/NG Test was examined in-house using a test panel composed of CT and NG cultures diluted into cobas® PCR Media and cobas® PCR Media mixed with

negative urine. The precision panel was designed to include members with either CT or NG at approximately the LOD for the panel matrix, members with both CT and NG at approximately the LOD and $2 . 5 \mathrm { \ : x }$ LOD for the panel matrix and a negative level. Testing was done with three unique lots of cobas® CT/NG Test reagents and three instruments for a total of 24 runs. A description of the precision panels and the study performance in $\%$ hit rate are shown in Table 11. All positive panel levels yielded the anticipated hit rates. All negative panel levels tested negative throughout the study.

Table 11: In-House Precision Study Hit Rate Analysis   

<table><tr><td rowspan=2 colspan=1>PanelNumber</td><td rowspan=2 colspan=1>Panel Matrix</td><td rowspan=1 colspan=2>Target Conc.</td><td rowspan=1 colspan=1>N</td><td rowspan=2 colspan=1>N PosCT</td><td rowspan=2 colspan=1>N PosNG</td><td rowspan=2 colspan=1>Hit Rate</td><td rowspan=1 colspan=2>95% CI</td></tr><tr><td rowspan=1 colspan=1>CT</td><td rowspan=1 colspan=1>NG</td><td rowspan=1 colspan=1>Tested</td><td rowspan=1 colspan=1>Lower</td><td rowspan=1 colspan=1>Upper</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>cobasPCR Media</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>144</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>2.5</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>cobasPCR Media</td><td rowspan=1 colspan=1>1 X LOD</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>144</td><td rowspan=1 colspan=1>144</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>97.5</td><td rowspan=1 colspan=1>100.0</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>cobasPCR Media</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>1XLOD</td><td rowspan=1 colspan=1>144</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>144</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>97.5</td><td rowspan=1 colspan=1>100.0</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>cobas® PCR Media</td><td rowspan=1 colspan=1>1XLOD</td><td rowspan=1 colspan=1>2.5 X LOD</td><td rowspan=1 colspan=1>144</td><td rowspan=1 colspan=1>144</td><td rowspan=1 colspan=1>144</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>97.5</td><td rowspan=1 colspan=1>100.0</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>cobasPCR Media</td><td rowspan=1 colspan=1>2.5 X LOD</td><td rowspan=1 colspan=1>1 X LOD</td><td rowspan=1 colspan=1>144</td><td rowspan=1 colspan=1>144</td><td rowspan=1 colspan=1>144</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>97.5</td><td rowspan=1 colspan=1>100.0</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>cobasPCR Media +Urine</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>144</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>2.5</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>cobas® PCR Media +Urine</td><td rowspan=1 colspan=1>1 X LOD</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>144</td><td rowspan=1 colspan=1>144</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>97.5</td><td rowspan=1 colspan=1>100.0</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>cobasPCR Media +Urine</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>1 X LOD</td><td rowspan=1 colspan=1>144</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>144</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>97.5</td><td rowspan=1 colspan=1>100.0</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>cobasPCR Media +Urine</td><td rowspan=1 colspan=1>1 X LOD</td><td rowspan=1 colspan=1>2.5 XLOD</td><td rowspan=1 colspan=1>144</td><td rowspan=1 colspan=1>144</td><td rowspan=1 colspan=1>144</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>97.5</td><td rowspan=1 colspan=1>100.0</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>cobasPCR Media +Urine</td><td rowspan=1 colspan=1>2.5 XLOD</td><td rowspan=1 colspan=1>1 X LOD</td><td rowspan=1 colspan=1>144</td><td rowspan=1 colspan=1>144</td><td rowspan=1 colspan=1>144</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>97.5</td><td rowspan=1 colspan=1>100.0</td></tr></table>

$\yen 99.3$ Hit Rate for NG. CT Hit Rate is $100 \%$

# 5. CLINICAL PERFORMANCE

The clinical performance characteristics of the cobas® CT/NG Test were established in two multi-center clinical investigations conducted in the United States. One study evaluated the reproducibility at one internal and two external testing sites. The other study evaluated the sensitivity, specificity, and predictive values of the cobas® CT/NG Test on clinical specimens.

# 5.1. Reproducibility

A Reproducibility Study was performed across lot, testing site, operator, run, and day for the cobas® CT/NG Test using 2 panels prepared from swabs and urine collected in cobas PCR Media. A run for cobas® pCR Media (urine or swab) included 3 replicates of each of 5 panel members and 1 positive and 1 negative control (17 total tests). If cobas® PCR Media panels were combined in a run, only 1 positive and 1 negative control were included (32 total tests). The 2 operators at each site performed 2 runs per day, for a total of 3 days of testing per operator per panel type (6 days of testing total for each panel type and reagent lot). Testing was performed with 2 reagent lots (6 days of testing per lot).

Overall, 74 runs were performed, and 72 valid runs were obtained for urine and swab panel types. The 2 invalid runs were due to instrument errors. A total of 1,080 tests were performed on the 5 panel members for each panel type in the valid runs. There was 1 invalid test result in the urine panel type, and 2 invalid test results in the swab panel type. These invalid tests were due to instrument errors.

All valid test results were included in the analyses that reported the percent agreement for CT and NG for each panel type separately. There were no false positive results for either analyte (CT and NG) for both panel types for negative panel members, thus giving negative percent agreement (NPA) of $100 \%$ for each analyte.

# 5.1.1. C. trachomatis (Table 12 and Table 13)

Percent agreement for the positive panel members was excellent across both panel types and panel members showing a positive percent agreement (PPA) of $100 \%$

Analysis of variance components of the Ct values from valid tests performed on positive panel members yielded overall CV $( \% )$ ranges from $1 . 1 \%$ to $1 . 5 \%$ for the urine panel type and $1 . 6 \%$ to $1 . 8 \%$ for the swab panel type.

Table 6: C. trachomatis: Percent Agreement by Panel Member for Lot, Site/Instrument, and Day — PCR Media/Urine   

<table><tr><td>Panel</td><td>Ct</td><td>Ct</td><td>Percent Agreement *</td></tr></table>

<table><tr><td rowspan=1 colspan=1>Member</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=3>Lot</td><td rowspan=1 colspan=3>SitelInstrument</td><td rowspan=1 colspan=3>Day</td></tr><tr><td rowspan=3 colspan=1>Negative CT,Negative NG</td><td rowspan=3 colspan=1>n/a</td><td rowspan=3 colspan=1>n/a</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>108/108</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>71/71</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>72172</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>107/107</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>72172</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>71/71</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>72/72</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>72172</td></tr><tr><td rowspan=3 colspan=1>1x LOD CT,Negative NG</td><td rowspan=3 colspan=1>0.54</td><td rowspan=3 colspan=1>1.5</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>108/108</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>72/72</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>72/72</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>108/108</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>72172</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>72172</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>72172</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>72/72</td></tr><tr><td rowspan=3 colspan=1>Negative CT,1x LOD NG</td><td rowspan=3 colspan=1>n/a</td><td rowspan=3 colspan=1>n/a</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>108/108</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>72172</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>72172</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>108/108</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>72/72</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>72/72</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>72172</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>72172</td></tr><tr><td rowspan=3 colspan=1>1x LOD CT,2.5x LOD NG</td><td rowspan=3 colspan=1>0.48</td><td rowspan=3 colspan=1>1.3</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>108/108</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>72172</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>72172</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>108/108</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>72/72</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>72/72</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>72/72</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>72172</td></tr><tr><td rowspan=3 colspan=1>2.5x LOD CT,1x LOD NG</td><td rowspan=3 colspan=1>0.40</td><td rowspan=3 colspan=1>1.1</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>108/108</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>72/72</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>72172</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>108/108</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>72/72</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>72172</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>72172</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>72172</td></tr></table>

\* For Negative samples, Percent Agreement $=$ (number of negative results/total valid results); For Positive samples, Percent Agreement $\equiv$ (number of positive results/total valid results)

Table 7: C. trachomatis: Percent Agreement by Panel Member for Lot, Site/Instrument, and Day — PCR Media/Swab   

<table><tr><td rowspan=2 colspan=1>PanelMember</td><td rowspan=2 colspan=1>CtSD</td><td rowspan=2 colspan=1>CtCV%</td><td rowspan=1 colspan=9>Percent Agreement *</td></tr><tr><td rowspan=1 colspan=3>Lot</td><td rowspan=1 colspan=3>SitelInstrument</td><td rowspan=1 colspan=3>Day</td></tr><tr><td rowspan=3 colspan=1>Negative CT,Negative NG</td><td rowspan=3 colspan=1>n/a</td><td rowspan=3 colspan=1>n/a</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>108/108</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>72/72</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>72172</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>108/108</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>72/72</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>72/72</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>72172</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>72172</td></tr><tr><td rowspan=3 colspan=1>1x LOd Ct,Negative NG</td><td rowspan=3 colspan=1>0.61</td><td rowspan=3 colspan=1>1.6</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>107/107</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>72/72</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>72/72</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>108/108</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>71/71</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>72/72</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>72172</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>71/71</td></tr><tr><td rowspan=3 colspan=1>Negative CT,1x LOD NG</td><td rowspan=3 colspan=1>n/a</td><td rowspan=3 colspan=1>n/a</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>108/108</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>72/72</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>72172</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>107/107</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>71/71</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>71/71</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>72/72</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>72172</td></tr><tr><td rowspan=3 colspan=1>1x Lod Ct,2.5x LOD NG</td><td rowspan=3 colspan=1>0.66</td><td rowspan=3 colspan=1>1.8</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>108/108</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>72/72</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>72172</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>108/108</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>72/72</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>72/72</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>72/72</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>72/72</td></tr><tr><td rowspan=3 colspan=1>2.5x LOD CT,1x LOD NG</td><td rowspan=3 colspan=1>0.59</td><td rowspan=3 colspan=1>1.6</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>108/108</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>72/72</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>72/72</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>108/108</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>72/72</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>72172</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>72/72</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>72172</td></tr></table>

\* For Negative samples, Percent Agreement (number of negative results/total valid results); For Positive samples, Percent Agreement $=$ (number of positive results/total valid results)

# 5.1.2. N. gonorrhoeae (Table 12 and Table 13)

Percent agreement for the positive panel members was excellent across all panel types and panel members. The lowest overall PPA was $9 9 . 5 2 \%$ for the "Negative CT, 1 x LOD NG" panel member for PCR Media/Urine panel type.

Analysis of variance components of the Ct values from valid tests performed on positive panel members yielded overall CV $( \% )$ ranges from $1 . 2 \%$ to $1 . 5 \%$ for the urine panel type and $1 . 4 \%$ to $1 . 9 \%$ for the swab panel type.

Table 8: N. gonorrhoeae: Percent Agreement by Panel Member for Lot, Site/Instrument, and Day — PCR Media/Urine   

<table><tr><td rowspan=2 colspan=1>PanelMember</td><td rowspan=2 colspan=1>CtSD</td><td rowspan=2 colspan=1>CtCV %</td><td rowspan=1 colspan=9>Percent Agreement </td></tr><tr><td rowspan=1 colspan=3>Lot</td><td rowspan=1 colspan=3>Site/Instrument</td><td rowspan=1 colspan=3>Day</td></tr><tr><td rowspan=3 colspan=1>Negative CT,Negative NG</td><td rowspan=3 colspan=1>n/a</td><td rowspan=3 colspan=1>n/a</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>108/108</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>71/71</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>72/72</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>107/107</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>72172</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>71/71</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>72/72</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>72/72</td></tr><tr><td rowspan=3 colspan=1>1x LOD CT,Negative NG</td><td rowspan=3 colspan=1>n/a</td><td rowspan=3 colspan=1>n/a</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>108/108</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>72/72</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>72/72</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>108/108</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>72/72</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>72/72</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>72172</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>72/72</td></tr><tr><td rowspan=3 colspan=1>Negative CT,1x LOD NG</td><td rowspan=3 colspan=1>0.53</td><td rowspan=3 colspan=1>1.5</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>99.1</td><td rowspan=1 colspan=1>107/108</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>72/72</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>72/72</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>108/108</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>72172</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>98.6</td><td rowspan=1 colspan=1>71/72</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>98.6</td><td rowspan=1 colspan=1>71/72</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>72/72</td></tr><tr><td rowspan=3 colspan=1>1x LOD CT,2.5x LOD NG</td><td rowspan=3 colspan=1>0.41</td><td rowspan=3 colspan=1>1.2</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>108/108</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>72172</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>72/172</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>108/108</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>72/72</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>72/72</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>72/72</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>72/72</td></tr><tr><td rowspan=3 colspan=1>2.5x LOD CT,1x LOD NG</td><td rowspan=3 colspan=1>0.54</td><td rowspan=3 colspan=1>1.5</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>108/108</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>72172</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>72/72</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>108/108</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>72/72</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>100.0$</td><td rowspan=1 colspan=1>72/72</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>72/72</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>72/72</td></tr></table>

1 For Negative samples, Percent Agreement $=$ (number of negative results/total valid results); For Positive samples, Percent Agreement $=$ (number of positive results/total valid results)

Table 9: N. gonorrhoeae: Percent Agreement by Panel Member for Lot, Site/Instrument, and Day — PCR Media/Swab   

<table><tr><td colspan="1" rowspan="2">PanelMember</td><td colspan="1" rowspan="2">CtSD</td><td colspan="1" rowspan="2">CtCv%</td><td colspan="9" rowspan="1">Percent Agreement 1</td></tr><tr><td colspan="3" rowspan="1">Lot</td><td colspan="3" rowspan="1">SitelInstrument</td><td colspan="3" rowspan="1">Day</td></tr><tr><td colspan="1" rowspan="3">Negative CT,Negative NG</td><td colspan="1" rowspan="3">n/a</td><td colspan="1" rowspan="3">n/a</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">100.0</td><td colspan="1" rowspan="1">108/108</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">100.0</td><td colspan="1" rowspan="1">72/72</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">100.0</td><td colspan="1" rowspan="1">72172</td></tr><tr><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">100.0</td><td colspan="1" rowspan="1">108/108</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">100.0</td><td colspan="1" rowspan="1">72/72</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">100.0</td><td colspan="1" rowspan="1">72/72</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">100.0</td><td colspan="1" rowspan="1">72/72</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">100.0</td><td colspan="1" rowspan="1">72172</td></tr><tr><td colspan="1" rowspan="3">1x LOD CT,Negative NG</td><td colspan="1" rowspan="3">n/a</td><td colspan="1" rowspan="3">n/a</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">100.0</td><td colspan="1" rowspan="1">107/107</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">100.0</td><td colspan="1" rowspan="1">72/72</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">100.0</td><td colspan="1" rowspan="1">72172</td></tr><tr><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">100.0</td><td colspan="1" rowspan="1">108/108</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">100.0</td><td colspan="1" rowspan="1">71/71</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">100.0</td><td colspan="1" rowspan="1">72172</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">100.0</td><td colspan="1" rowspan="1">72/72</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">100.0</td><td colspan="1" rowspan="1">71/71</td></tr><tr><td colspan="1" rowspan="3">Negative CT,1x LOD NG</td><td colspan="1" rowspan="3">0.68</td><td colspan="1" rowspan="3">1.8</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">100.0</td><td colspan="1" rowspan="1">108/108</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">100.0</td><td colspan="1" rowspan="1">72172</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">100.0</td><td colspan="1" rowspan="1">72172</td></tr><tr><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">100.0</td><td colspan="1" rowspan="1">107/107</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">100.0</td><td colspan="1" rowspan="1">71/71</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">100.0</td><td colspan="1" rowspan="1">71/71</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">100.0</td><td colspan="1" rowspan="1">72/72</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">100.0</td><td colspan="1" rowspan="1">72/72</td></tr><tr><td colspan="1" rowspan="2">PanelMember</td><td colspan="1" rowspan="2">CtSD</td><td colspan="1" rowspan="2">CtCV%</td><td colspan="9" rowspan="1">Percent Agreement 1</td></tr><tr><td colspan="3" rowspan="1">Lot</td><td colspan="3" rowspan="1">SitelInstrument</td><td colspan="3" rowspan="1">Day</td></tr><tr><td colspan="1" rowspan="3">1x LOD CT,2.5x LOD NG</td><td colspan="1" rowspan="3">0.49</td><td colspan="1" rowspan="3">1.4</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">100.0</td><td colspan="1" rowspan="1">108/108</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">100.0</td><td colspan="1" rowspan="1">72/72</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">100.0</td><td colspan="1" rowspan="1">72/72</td></tr><tr><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">100.0</td><td colspan="1" rowspan="1">108/108</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">100.0</td><td colspan="1" rowspan="1">72172</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">100.0</td><td colspan="1" rowspan="1">72172</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">100.0</td><td colspan="1" rowspan="1">72/72</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">100.0</td><td colspan="1" rowspan="1">72172</td></tr><tr><td colspan="1" rowspan="3">2.5x LOD CT,1x LOD NG</td><td colspan="1" rowspan="3">0.71</td><td colspan="1" rowspan="3">1.9</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">100.0</td><td colspan="1" rowspan="1">108/108</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">100.0</td><td colspan="1" rowspan="1">72/72</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">100.0</td><td colspan="1" rowspan="1">72/172</td></tr><tr><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">100.0</td><td colspan="1" rowspan="1">108/108</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">100.0</td><td colspan="1" rowspan="1">72/72</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">100.0</td><td colspan="1" rowspan="1">72/72</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">100.0</td><td colspan="1" rowspan="1">72172</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">100.0</td><td colspan="1" rowspan="1">72/72</td></tr></table>

1 For Negative samples, Percent Agreement $\mathbf { \delta m }$ (number of negative results/total valid results); For Positive samples, Percent Agreement $\equiv$ (number of positive results/total valid results)

# 5.2. Clinical Specimen Study

# 5.2.1. Study Design

Performance characteristics of the cobas® CT/NG Test were evaluated in a multi-center clinical study conducted in the United States. Specimens were collected at 12 geographically diverse sites including OB-GYN practices, public and private STD clinics, and family planning centers. A total of 2.851 evaluable male and female, symptomatic and asymptomatic subjects were enrolled. Subjects were classified as symptomatic if the subject reported symptoms indicative of CT or NG infection. Specimens collected from each female subject included urine, a clinician- or self-collected vaginal swab, endocervical swabs, and a cervical sample in PreservCyt® Solution (Hologic Corporation, Bedford MA) obtained with a spatula/cytobrush or a broom. Male subjects provided urethral swabs and urine specimens. Specimens were tested using the cobas® CT/NG Test and two commercially available nucleic acid amplification tests (NAAT) for CT and NG. The NAATs were used as reference assays in the clinical study.

For females, urine specimens were collected first. If a cervical cytology test was a scheduled part of the visit, that sample was taken next, followed by a vaginal swab and then endocervical swabs. If a cervical cytology test was not a scheduled part of the visit, a vaginal swab was taken next, followed by endocervical swabs and then the cervical specimen. The order of endocervical swab collection as well as clinician- or self-collection of the vaginal swab was alternated to minimize collection bias. For males, the urethral swabs were collected first in alternating order and then the urine specimen was collected. All specimens were taken and stored according to the manufacturer's instructions.

# 5.2.2. Determination of Patient Infected Status

For each subject, a patient infected status (PIS) was determined based on the combined results from the reference assays. A subject was categorized as infected for CT or NG if a minimum of two positive results (at least one from each reference NAAT) was reported, as described in Table 14. Female subjects with positive results on both reference urine specimens and negative results on both reference endocervical swab specimens and the reference cervical sample were categorized as infected for urine and not infected for swab specimens. A subject was classified as non-infected if at least one of the reference NAATs reported negative results for all sample types.

Table 10: Determination of Patient Infected Status   

<table><tr><td rowspan=1 colspan=1>NAAT1Urine/Endocervical orUrethral Swab</td><td rowspan=1 colspan=1>NAAT2Urine/Endocervical orUrethral Swab</td><td rowspan=1 colspan=1>NAAT2Cervical Specimen inPreservCyt</td><td rowspan=1 colspan=1>Patient Infected Status</td></tr><tr><td rowspan=1 colspan=1>+/+</td><td rowspan=1 colspan=1>+1+</td><td rowspan=1 colspan=1>+or-</td><td rowspan=1 colspan=1>Infected</td></tr><tr><td rowspan=1 colspan=1>+/+</td><td rowspan=1 colspan=1>+/-or-1+</td><td rowspan=1 colspan=1>+or-</td><td rowspan=1 colspan=1>Infected</td></tr><tr><td rowspan=1 colspan=1>+/-or-1+</td><td rowspan=1 colspan=1>+1+</td><td rowspan=1 colspan=1>+ or-</td><td rowspan=1 colspan=1>Infected</td></tr><tr><td rowspan=1 colspan=1>+/-</td><td rowspan=1 colspan=1>-1+</td><td rowspan=1 colspan=1>+or-</td><td rowspan=1 colspan=1>Infected</td></tr><tr><td rowspan=1 colspan=1>-1+</td><td rowspan=1 colspan=1>+1-</td><td rowspan=1 colspan=1>+or-</td><td rowspan=1 colspan=1>Infected</td></tr><tr><td rowspan=1 colspan=1>-1+</td><td rowspan=1 colspan=1>-1+</td><td rowspan=1 colspan=1>+or-</td><td rowspan=1 colspan=1>Infected</td></tr><tr><td rowspan=1 colspan=1>+/-</td><td rowspan=1 colspan=1>+1-</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>Infected</td></tr><tr><td rowspan=1 colspan=1>+/-</td><td rowspan=1 colspan=1>+1-</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Infected (Urine)Non-infected (Swabs)</td></tr><tr><td rowspan=1 colspan=1>+/-or-1+</td><td rowspan=1 colspan=1>-1-</td><td rowspan=1 colspan=1>+ or-</td><td rowspan=1 colspan=1>Non-Infected</td></tr><tr><td rowspan=1 colspan=1>+/+</td><td rowspan=1 colspan=1>-1-</td><td rowspan=1 colspan=1>+or-</td><td rowspan=1 colspan=1>Non-Infected</td></tr><tr><td rowspan=1 colspan=1>-/-</td><td rowspan=1 colspan=1>+/+</td><td rowspan=1 colspan=1>+ or-</td><td rowspan=1 colspan=1>Non-Infected</td></tr><tr><td rowspan=1 colspan=1>-1-</td><td rowspan=1 colspan=1>+1-or-1+</td><td rowspan=1 colspan=1>+or-</td><td rowspan=1 colspan=1>Non-Infected</td></tr><tr><td rowspan=1 colspan=1>-1-</td><td rowspan=1 colspan=1>-1-</td><td rowspan=1 colspan=1>+ or-</td><td rowspan=1 colspan=1>Non-Infected</td></tr></table>

If patient infected status could not be determined due to missing and/or indeterminate results from the reference tests, the subject was excluded from the analysis. PIS could not be determined for one subject.

# 5.2.3. Study Results

Table 15 through Table 22 summarize the data from the clinical specimen study.

Results from the cobas® CT/NG Test were compared with the PIS for calculation of test sensitivity and specificity. A total of 21,988 CT and 21,987 NG results were analyzed by $\operatorname { s e x } ,$ EY sample type, and the presence of symptoms. The overall sensitivity and specificity for CT was $9 5 . 7 \%$ and $9 9 . 7 \%$ The overall prevalence was $9 . 0 \%$ for CT $6 . 3 \%$ in women and $1 6 . 4 \%$ in men). The overall sensitivity and specificity for NG was $9 9 . 0 \%$ and $9 9 . 9 \%$ The overall prevalence was $3 . 6 \%$ for NG ( $1 . 6 \%$ in women, $9 . 2 \%$ in men). Sensitivity, specificity, and prevalence for CT are presented in Table I5. Sensitivity, specificity, and prevalence for NG are presented in Table 16.

A comparison of patient infected status, test results from the reference tests and test results from the cobas® CT/NG Test was performed. CT results for female subjects are presented in Table 17, and for male subjects in Table 18. NG results for female subjects are presented in Table 19, and for male subjects in Table 20.

The positive and negative predictive values (PPV and NPV) were calculated using hypothetical prevalence rates and the cobas® CT/NG Test sensitivity and specificity determined in the study. The positive and negative predictive value estimates for CT are presented in Table 21, and for NG in Table 22.

Table 11: CT Clinical Performance Compared with Patient Infected Status by Gender, Sample Type, and Symptom Status   

<table><tr><td colspan="1" rowspan="1">SampleTeye{}$</td><td colspan="1" rowspan="1">Symptom Status</td><td colspan="1" rowspan="1">Total(n)</td><td colspan="1" rowspan="1">SENS</td><td colspan="1" rowspan="1">95% CI</td><td colspan="1" rowspan="1">SPEC</td><td colspan="1" rowspan="1">95% CI</td><td colspan="1" rowspan="1">PREV(%)</td><td colspan="1" rowspan="1">PPV(%)</td><td colspan="1" rowspan="1">NPV(%)</td></tr><tr><td colspan="10" rowspan="1">Female</td></tr><tr><td colspan="1" rowspan="2">VG</td><td colspan="1" rowspan="1">Symp</td><td colspan="1" rowspan="1">1073</td><td colspan="1" rowspan="1">93.8%(75/80)</td><td colspan="1" rowspan="1">(86.2%,97.3%)</td><td colspan="1" rowspan="1">99.7%(990/993)</td><td colspan="1" rowspan="1">(99.1%,99.9%)</td><td colspan="1" rowspan="1">7.5</td><td colspan="1" rowspan="1">96.2</td><td colspan="1" rowspan="1">99.5</td></tr><tr><td colspan="1" rowspan="1">Asymp</td><td colspan="1" rowspan="1">1010</td><td colspan="1" rowspan="1">94.1%(48/51)</td><td colspan="1" rowspan="1">(84.1%,98.0%)</td><td colspan="1" rowspan="1">99.7%(956/959)</td><td colspan="1" rowspan="1">(99.1%,99.9%)</td><td colspan="1" rowspan="1">5.0</td><td colspan="1" rowspan="1">94.1</td><td colspan="1" rowspan="1">99.7</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Overall</td><td colspan="1" rowspan="1">2083</td><td colspan="1" rowspan="1">93.9%(123/131)</td><td colspan="1" rowspan="1">(88.4%,96.9%)</td><td colspan="1" rowspan="1">99.7%(1946/1952)</td><td colspan="1" rowspan="1">(99.3%,99.9%)</td><td colspan="1" rowspan="1">6.3</td><td colspan="1" rowspan="1">95.3</td><td colspan="1" rowspan="1">99.6</td></tr><tr><td colspan="10" rowspan="1">Male</td></tr><tr><td colspan="1" rowspan="3">UR.</td><td colspan="1" rowspan="1">Symp</td><td colspan="1" rowspan="1">296</td><td colspan="1" rowspan="1">97.3%(72174)</td><td colspan="1" rowspan="1">(90.7%,99.3%)</td><td colspan="1" rowspan="1">99.5%(221/222)</td><td colspan="1" rowspan="1">(97.5%,99.9%)</td><td colspan="1" rowspan="1">25.0</td><td colspan="1" rowspan="1">98.6</td><td colspan="1" rowspan="1">99.1</td></tr><tr><td colspan="1" rowspan="1">Asymp</td><td colspan="1" rowspan="1">472</td><td colspan="1" rowspan="1">98.1%(51/52)</td><td colspan="1" rowspan="1">(89.9%,99.7%)</td><td colspan="1" rowspan="1">99.5%(418/420)</td><td colspan="1" rowspan="1">(98.3%,99.9%)</td><td colspan="1" rowspan="1">11.0</td><td colspan="1" rowspan="1">96.2</td><td colspan="1" rowspan="1">99.8</td></tr><tr><td colspan="1" rowspan="1">Overall</td><td colspan="1" rowspan="1">768</td><td colspan="1" rowspan="1">97.6%(123/126)</td><td colspan="1" rowspan="1">(93.2%,99.2%)</td><td colspan="1" rowspan="1">99.5%(639/642)</td><td colspan="1" rowspan="1">(98.6%,99.8%)</td><td colspan="1" rowspan="1">16.4</td><td colspan="1" rowspan="1">97.6</td><td colspan="1" rowspan="1">99.5</td></tr><tr><td colspan="2" rowspan="1">All Combined</td><td colspan="1" rowspan="1">2851</td><td colspan="1" rowspan="1">95.7%(246/257)</td><td colspan="1" rowspan="1">(92.5%,97.6%)</td><td colspan="1" rowspan="1">99.7%(2585/2594)</td><td colspan="1" rowspan="1">(99.3%,99.8%)</td><td colspan="1" rowspan="1">9.0</td><td colspan="1" rowspan="1">96.5</td><td colspan="1" rowspan="1">99.6</td></tr></table>

EY $v G \cdot S =$ self-collected vaginal swab; UR $\equiv$ urine. Symp symptomatic; Asymp $=$ asymptomatic. o summary table. Note: Cl = (score) confidence interval; PREV $\equiv$ prevalence; SENS $\mathbf { \equiv }$ sensitivity; SPEC $=$ specificity; $\mathsf { P P V } =$ positive predictive value; NPV $\eqcirc$ negative predictive value.

Table 12: NG Clinical Performance Compared With Patient Infected Status by Gender, Sample Type, and Symptom Status   

<table><tr><td colspan="1" rowspan="1">SampleType}$</td><td colspan="1" rowspan="1">Symptom Status</td><td colspan="1" rowspan="1">Total(n)</td><td colspan="1" rowspan="1">SENS</td><td colspan="1" rowspan="1">95% CI</td><td colspan="1" rowspan="1">SPEC</td><td colspan="1" rowspan="1">95% CI</td><td colspan="1" rowspan="1">PREV(%)</td><td colspan="1" rowspan="1">PPV(%)</td><td colspan="1" rowspan="1">NPV(%)</td></tr><tr><td colspan="10" rowspan="1">Female</td></tr><tr><td colspan="1" rowspan="3">VG</td><td colspan="1" rowspan="1">Symp</td><td colspan="1" rowspan="1">1073</td><td colspan="1" rowspan="1">95.7%(22/23)</td><td colspan="1" rowspan="1">(79.0%,99.2%)</td><td colspan="1" rowspan="1">99.9%(1049/1050)</td><td colspan="1" rowspan="1">(99.5%,100.0%)</td><td colspan="1" rowspan="1">2.1</td><td colspan="1" rowspan="1">95.7</td><td colspan="1" rowspan="1">99.9</td></tr><tr><td colspan="1" rowspan="1">Asymp</td><td colspan="1" rowspan="1">1010</td><td colspan="1" rowspan="1">100.0%(10/10)</td><td colspan="1" rowspan="1">(72.2%,100.0%)</td><td colspan="1" rowspan="1">100.0%(1000/1000)</td><td colspan="1" rowspan="1">(99.6%,100.0%)</td><td colspan="1" rowspan="1">1.0</td><td colspan="1" rowspan="1">100.0</td><td colspan="1" rowspan="1">100.0</td></tr><tr><td colspan="1" rowspan="1">Overall</td><td colspan="1" rowspan="1">2083</td><td colspan="1" rowspan="1">97.0%(32/33)</td><td colspan="1" rowspan="1">(84.7%,99.5%)</td><td colspan="1" rowspan="1">100.0%(2049/2050)</td><td colspan="1" rowspan="1">(99.7%,100.0%)</td><td colspan="1" rowspan="1">1.6</td><td colspan="1" rowspan="1">97.0</td><td colspan="1" rowspan="1">100.0</td></tr><tr><td colspan="10" rowspan="1">Male</td></tr><tr><td colspan="1" rowspan="3">UR</td><td colspan="1" rowspan="1">Symp</td><td colspan="1" rowspan="1">296</td><td colspan="1" rowspan="1">100.0%(64/64)</td><td colspan="1" rowspan="1">(94.3%,100.0%)</td><td colspan="1" rowspan="1">99.1%(230/232)</td><td colspan="1" rowspan="1">(96.9%,99.8%)</td><td colspan="1" rowspan="1">21.6</td><td colspan="1" rowspan="1">97.0</td><td colspan="1" rowspan="1">100.0</td></tr><tr><td colspan="1" rowspan="1">Asymp</td><td colspan="1" rowspan="1">472</td><td colspan="1" rowspan="1">100.0%(717)</td><td colspan="1" rowspan="1">(64.6%,100.0%)</td><td colspan="1" rowspan="1">100.0%(465/465)</td><td colspan="1" rowspan="1">(99.2%,100.0%)</td><td colspan="1" rowspan="1">1.5</td><td colspan="1" rowspan="1">100.0</td><td colspan="1" rowspan="1">100.0</td></tr><tr><td colspan="1" rowspan="1">Overall</td><td colspan="1" rowspan="1">768</td><td colspan="1" rowspan="1">100.0%(71/71)</td><td colspan="1" rowspan="1">(94.9%,100.0%)</td><td colspan="1" rowspan="1">99.7%(695/697)</td><td colspan="1" rowspan="1">(99.0%,99.9%)</td><td colspan="1" rowspan="1">9.2</td><td colspan="1" rowspan="1">97.3</td><td colspan="1" rowspan="1">100.0</td></tr><tr><td colspan="2" rowspan="1">All Combined</td><td colspan="1" rowspan="1">2851</td><td colspan="1" rowspan="1">99.0%(103/104)</td><td colspan="1" rowspan="1">(94.8%,99.8%)</td><td colspan="1" rowspan="1">99.9%(2744/2747)</td><td colspan="1" rowspan="1">(99.7%,100.0%)</td><td colspan="1" rowspan="1">3.6</td><td colspan="1" rowspan="1">97.2</td><td colspan="1" rowspan="1">100.0</td></tr></table>

$v G - S =$ self-collected vaginal swab; UR $\equiv$ urine.   
Symp $\equiv$ symptomatic; Asymp $\equiv$ asymptomatic.   
endocervical swab (urethral swab for males) and/or the urine specimen.   
summary table.   
Note: $\mathsf { C l } = \{ \mathsf { s c o r e } \}$ confidence interval; PREV $\equiv$ prevalence; SENS sensitivity; SPEC $\Bumpeq$ specificity;   
$p P V =$ positive predictive value; $N P V =$ negative predictive value.

Table 13: CT Positive/Negative Analysis for Female Patient Infected Status   

<table><tr><td rowspan=2 colspan=1>Patient InfectedStatus</td><td rowspan=1 colspan=2>NAAT1</td><td rowspan=1 colspan=3>NAAT2</td><td rowspan=1 colspan=1>cobas CT/NGTest</td><td rowspan=1 colspan=2>Symptom Status</td><td rowspan=2 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>SW</td><td rowspan=1 colspan=1>UR</td><td rowspan=1 colspan=1>SW</td><td rowspan=1 colspan=1>UR</td><td rowspan=1 colspan=1>PCPre</td><td rowspan=1 colspan=1>VG</td><td rowspan=1 colspan=1>Symp</td><td rowspan=1 colspan=1>Asymp</td></tr><tr><td rowspan=1 colspan=1>Infected</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>61</td><td rowspan=1 colspan=1>39</td><td rowspan=1 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>Infected</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>6</td></tr><tr><td rowspan=1 colspan=1>Infected</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>5</td></tr><tr><td rowspan=1 colspan=1>Infected</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>NA</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>3</td></tr><tr><td rowspan=1 colspan=1>Infected</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>3</td></tr><tr><td rowspan=1 colspan=1>Infected</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>2</td></tr><tr><td rowspan=1 colspan=1>Infected</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>+$</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>2</td></tr><tr><td rowspan=1 colspan=1>Infected</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>+$</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=1 colspan=1>Infected</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>+$</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=1 colspan=1>Infected</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=1 colspan=1>Infected</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=1 colspan=1>Infected</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=1 colspan=1>Infected</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=1 colspan=1>Infected</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>+}$</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=1 colspan=1>Infected</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=1 colspan=1>Infected</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=1 colspan=1>Infected</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>+$</td><td rowspan=1 colspan=1>NA</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=1 colspan=1>Total Infected</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>51</td><td rowspan=1 colspan=1>131</td></tr><tr><td rowspan=1 colspan=1>Non-Infected</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>:</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>957</td><td rowspan=1 colspan=1>911</td><td rowspan=1 colspan=1>1868</td></tr><tr><td rowspan=1 colspan=1>Non-Infected</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>NA</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>24</td><td rowspan=1 colspan=1>40</td></tr><tr><td rowspan=1 colspan=1>Non-Infected</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>=</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>11</td></tr><tr><td rowspan=1 colspan=1>Non-Infected</td><td rowspan=1 colspan=1>NA</td><td rowspan=1 colspan=1>NA</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>9</td></tr><tr><td rowspan=1 colspan=1>Non-Infected</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>3</td></tr><tr><td rowspan=1 colspan=1>Non-Infected</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>3</td></tr><tr><td rowspan=1 colspan=1>Non-Infected</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>−</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>3</td></tr><tr><td rowspan=1 colspan=1>Non-Infected</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>2</td></tr><tr><td rowspan=1 colspan=1>Non-Infected</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>2</td></tr><tr><td rowspan=1 colspan=1>Non-Infected</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>NA</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>2</td></tr><tr><td rowspan=1 colspan=1>Non-Infected</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>NA</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td></tr><tr><td rowspan=1 colspan=1>Non-Infected</td><td rowspan=1 colspan=1>NA</td><td rowspan=1 colspan=1>−</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td></tr><tr><td rowspan=1 colspan=1>Non-Infected</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=1 colspan=1>Non-Infected</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>+$</td><td rowspan=1 colspan=1>+$</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=1 colspan=1>Non-Infected</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=1 colspan=1>Non-Infected</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=1 colspan=1>Non-Infected</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>−</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>NA</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=1 colspan=1>Total Non-Infected</td><td></td><td></td><td></td><td></td><td></td><td></td><td rowspan=1 colspan=1>993</td><td rowspan=1 colspan=1>959</td><td rowspan=1 colspan=1>1952</td></tr></table>

Symp $=$ symptomatic; Asymp asymptomatic. o il specimens and the PreservCyt specimen (NAAT2) were negative and the urine specimens were positive. summary table. Note: $^ +$ Note: $\mathbb { S } \mathbb { N } =$ endocervical swab; UR $=$ urine; $\forall \mathsf { G } =$ vaginal swab; PC Pre $=$ PreservCyt (pre-aliquot).

Table 14: CT Positive/Negative Analysis for Male Patient Infected Status   

<table><tr><td rowspan=2 colspan=1>PatientInfectedStatus</td><td rowspan=1 colspan=2>NAAT1</td><td rowspan=1 colspan=2>NAAT2</td><td rowspan=1 colspan=1>cobasCT/NG Test</td><td rowspan=1 colspan=2>Symptom Status</td><td rowspan=2 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>SW</td><td rowspan=1 colspan=1>UR</td><td rowspan=1 colspan=1>SW</td><td rowspan=1 colspan=1>UR</td><td rowspan=1 colspan=1>UR</td><td rowspan=1 colspan=1>Symp</td><td rowspan=1 colspan=1>Asymp</td></tr><tr><td rowspan=1 colspan=1>Infected</td><td rowspan=1 colspan=1>$+rac$</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>67</td><td rowspan=1 colspan=1>43</td><td rowspan=1 colspan=1>110</td></tr><tr><td rowspan=1 colspan=1>Infected</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>6</td></tr><tr><td rowspan=1 colspan=1>Infected</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>+$</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>3</td></tr><tr><td rowspan=1 colspan=1>Infected</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>+$</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>2</td></tr><tr><td rowspan=1 colspan=1>Infected</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>+frac}$</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=1 colspan=1>Infected</td><td rowspan=1 colspan=1>+$</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=1 colspan=1>Infected</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=1 colspan=1>Infected</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=1 colspan=1>Infected</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=1 colspan=1>Total Infected</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>74</td><td rowspan=1 colspan=1>52.</td><td rowspan=1 colspan=1>126</td></tr><tr><td rowspan=1 colspan=1>Non-Infected</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>218</td><td rowspan=1 colspan=1>412</td><td rowspan=1 colspan=1>630</td></tr><tr><td rowspan=1 colspan=1>Non-Infected</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>2</td></tr><tr><td rowspan=1 colspan=1>Non-Infected</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>2</td></tr><tr><td rowspan=1 colspan=1>Non-Infected</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>$\frac}$</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>2</td></tr><tr><td rowspan=1 colspan=1>Non-Infected</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>2</td></tr><tr><td rowspan=1 colspan=1>Non-Infected</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=1 colspan=1>Non-Infected</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=1 colspan=1>Non-Infected</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=1 colspan=1>Non-Infected</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=1 colspan=6>Total Non-Infected</td><td rowspan=1 colspan=1>222</td><td rowspan=1 colspan=1>420</td><td rowspan=1 colspan=1>642</td></tr></table>

Symp symptomatic; Asymp asymptomatic. and/or the urine specimen. table. Note: $^ +$ denotes Positive; - denotes Negative. Note: $\mathbb { S } W =$ urethral swab; $\mathtt { U R } =$ urine.

Table 15: NG Positive/Negative Analysis for Female Patient Infected Status   

<table><tr><td colspan="1" rowspan="2">Patient InfectedStatus</td><td colspan="2" rowspan="1">NAAT1</td><td colspan="3" rowspan="1">NAAT2</td><td colspan="1" rowspan="1">cobas CT/NGTest</td><td colspan="2" rowspan="1">Symptom Status</td><td colspan="1" rowspan="2">Total</td></tr><tr><td colspan="1" rowspan="1">SW</td><td colspan="1" rowspan="1">UR</td><td colspan="1" rowspan="1">SW</td><td colspan="1" rowspan="1">UR</td><td colspan="1" rowspan="1">PCPre</td><td colspan="1" rowspan="1">VG</td><td colspan="1" rowspan="1">Symp</td><td colspan="1" rowspan="1">Asymp</td></tr><tr><td colspan="1" rowspan="1">infected</td><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1">16</td><td colspan="1" rowspan="1">9</td><td colspan="1" rowspan="1">25</td></tr><tr><td colspan="1" rowspan="1">Infected</td><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">3</td></tr><tr><td colspan="1" rowspan="1">Infected</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">2</td></tr><tr><td colspan="1" rowspan="1">Infected</td><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">1</td></tr><tr><td colspan="1" rowspan="1">Infected</td><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1">+$</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">1</td></tr><tr><td colspan="1" rowspan="1">Infected</td><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">1</td></tr><tr><td colspan="1" rowspan="1">Total Infected</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="4" rowspan="1">EY</td><td colspan="1" rowspan="1">23</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">33</td></tr><tr><td colspan="1" rowspan="1">Non-Infected</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1">1017</td><td colspan="1" rowspan="1">958</td><td colspan="1" rowspan="1">1975</td></tr><tr><td colspan="1" rowspan="1">Non-Infected</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">18</td><td colspan="1" rowspan="1">26</td><td colspan="1" rowspan="1">44</td></tr><tr><td colspan="1" rowspan="1">Non-Infected</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">9</td><td colspan="1" rowspan="1">9</td></tr><tr><td colspan="1" rowspan="1">Non-Infected</td><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">5</td></tr><tr><td colspan="1" rowspan="1">Non-Infected</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">4</td></tr><tr><td colspan="1" rowspan="1">Non-Infected</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">4</td></tr><tr><td colspan="1" rowspan="1">Non-Infected</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">2</td></tr><tr><td colspan="1" rowspan="1">Non-Infected</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">:</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">2</td></tr><tr><td colspan="1" rowspan="1">Non-Infected</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">2</td></tr><tr><td colspan="1" rowspan="1">Non-Infected</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">−</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">1</td></tr><tr><td colspan="1" rowspan="1">Non-Infected</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1">:</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">1</td></tr><tr><td colspan="1" rowspan="1">Non-Infected</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">1</td></tr><tr><td colspan="1" rowspan="1">Total Non-Infected</td><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="1" rowspan="1">1050</td><td colspan="1" rowspan="1">1000</td><td colspan="1" rowspan="1">2050</td></tr></table>

Symp $=$ symptomatic; Asymp $=$ asymptomatic. oA endocervical swab and/or the urine specimen. summary table. Note: $^ { + }$ Note: $\mathbb { S } W =$ endocervical swab: UR urine; $\forall G =$ vaginal swab; PC Pre $=$ PreservCyt (pre-aliquot).

Table 16: NG Positive/Negative Analysis for Male Patient Infected Status   

<table><tr><td rowspan=2 colspan=1>PatientInfectedStatus</td><td rowspan=1 colspan=2>NAAT1</td><td rowspan=1 colspan=2>NAAT2</td><td rowspan=1 colspan=1>cobasCT/NG Test</td><td rowspan=1 colspan=2>Symptom Status</td><td rowspan=2 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>SW</td><td rowspan=1 colspan=1>UR</td><td rowspan=1 colspan=1>SW</td><td rowspan=1 colspan=1>UR</td><td rowspan=1 colspan=1>UR</td><td rowspan=1 colspan=1>Symp</td><td rowspan=1 colspan=1>Asymp</td></tr><tr><td rowspan=1 colspan=1>Infected</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>63</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>70</td></tr><tr><td rowspan=1 colspan=1>Infected</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=1 colspan=6>Total Infected</td><td rowspan=1 colspan=1>64</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>71</td></tr><tr><td rowspan=1 colspan=1>Non-Infected</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>227</td><td rowspan=1 colspan=1>464</td><td rowspan=1 colspan=1>691</td></tr><tr><td rowspan=1 colspan=1>Non-Infected</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td></tr><tr><td rowspan=1 colspan=1>Non-Infected</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>−</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>2</td></tr><tr><td rowspan=1 colspan=1>Non-Infected</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=1 colspan=1>Non-Infected</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=1 colspan=6>Total Non-Infected</td><td rowspan=1 colspan=1>232</td><td rowspan=1 colspan=1>465</td><td rowspan=1 colspan=1>697</td></tr></table>

Symp $=$ symptomatic; Asymp $=$ asymptomatic. swab and/or the urine specimen. table. Note: $^ +$ denotes Positive; - denotes Negative. Note: $\mathbb { S } \mathbb { W } =$ urethral swab; $\mathtt { U R } =$ urine.

Table 17: Positive Predictive Value and Negative Predictive Value for Hypothetical CT Prevalence   

<table><tr><td rowspan=1 colspan=1>Prevalence (%)</td><td rowspan=1 colspan=1>Sensitivity (%)</td><td rowspan=1 colspan=1>Specificity (%)</td><td rowspan=1 colspan=1>PPV {%)</td><td rowspan=1 colspan=1>NPV (%)</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>95.7</td><td rowspan=1 colspan=1>99.7</td><td rowspan=1 colspan=1>73.6</td><td rowspan=1 colspan=1>100.0</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>95.7</td><td rowspan=1 colspan=1>99.7</td><td rowspan=1 colspan=1>89.5</td><td rowspan=1 colspan=1>99.9</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>95.7</td><td rowspan=1 colspan=1>99.7</td><td rowspan=1 colspan=1>93.6</td><td rowspan=1 colspan=1>99.8</td></tr><tr><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>95.7</td><td rowspan=1 colspan=1>99.7</td><td rowspan=1 colspan=1>96.8</td><td rowspan=1 colspan=1>99.5</td></tr><tr><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>95.7</td><td rowspan=1 colspan=1>99.7</td><td rowspan=1 colspan=1>98.0</td><td rowspan=1 colspan=1>99.2</td></tr><tr><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>95.7</td><td rowspan=1 colspan=1>99.7</td><td rowspan=1 colspan=1>98.6</td><td rowspan=1 colspan=1>98.9</td></tr><tr><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>95.7</td><td rowspan=1 colspan=1>99.7</td><td rowspan=1 colspan=1>99.2</td><td rowspan=1 colspan=1>98.2</td></tr><tr><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>95.7</td><td rowspan=1 colspan=1>99.7</td><td rowspan=1 colspan=1>99.6</td><td rowspan=1 colspan=1>95.9</td></tr></table>

and male subjects. Note: $\mathsf { P P V } =$ positive predictive value; ${ \mathsf { N P V } } =$ negative predictive value.

Table 18: Positive Predictive Value and Negative Predictive Value for Hypothetical NG Prevalence   

<table><tr><td rowspan=1 colspan=1>Prevalence (%)</td><td rowspan=1 colspan=1>Sensitivity (%)</td><td rowspan=1 colspan=1>Specificity (%)</td><td rowspan=1 colspan=1>PPV (%)</td><td rowspan=1 colspan=1>NPV (%)</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>99.0</td><td rowspan=1 colspan=1>99.9</td><td rowspan=1 colspan=1>90.2</td><td rowspan=1 colspan=1>100.0</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>99.0</td><td rowspan=1 colspan=1>99.9</td><td rowspan=1 colspan=1>96.6</td><td rowspan=1 colspan=1>100.0</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>99.0</td><td rowspan=1 colspan=1>99.9</td><td rowspan=1 colspan=1>97.9</td><td rowspan=1 colspan=1>99.9</td></tr><tr><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>99.0</td><td rowspan=1 colspan=1>99.9</td><td rowspan=1 colspan=1>99.0</td><td rowspan=1 colspan=1>99.9</td></tr><tr><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>99.0</td><td rowspan=1 colspan=1>99.9</td><td rowspan=1 colspan=1>99.4</td><td rowspan=1 colspan=1>99.8</td></tr><tr><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>99.0</td><td rowspan=1 colspan=1>99.9</td><td rowspan=1 colspan=1>99.6</td><td rowspan=1 colspan=1>99.8</td></tr><tr><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>99.0</td><td rowspan=1 colspan=1>99.9</td><td rowspan=1 colspan=1>99.7</td><td rowspan=1 colspan=1>99.6</td></tr><tr><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>99.0</td><td rowspan=1 colspan=1>99.9</td><td rowspan=1 colspan=1>99.9</td><td rowspan=1 colspan=1>99.0</td></tr></table>

subjects. Note: $\mathsf { P V } =$ positive predictive value; $\mathbf { N P V } =$ negative predictive value.

# 5..4. Conclusion Drawn from Clinical Specimen Study

In b symptomatic nd asymptomatic patents, he cobas®G Test fers hig sensviy, specificity, and positive and negative predictive values for the direct, qualitative detection of CT and NG in male urine specimens and self-collected vaginal swabs. These results are of key importance from both diagnostic and public health perspectives.

# 6. CONCLUSION

A comparison of the intended use, technological characteristics, and the results of non-clinical analytical and clinical performance studies demonstrate that the cobas® CT/NG Test is safe and effective when used in accordance with the product labeling.

Mr. James R. Bonds Director, Regulatory Affairs Roche Molecular Systems, Inc. 4300 Hacienda Drive Pleasanton, CA 94588-0900

Re: K110923 Trade Name: cobas® CT/NG Test Regulation Number: 21 CFR $\ S 8 6 6 . 3 1 2 0$ EPY Regulation Name: Chlamydia serological reagents Regulatory Class: Class I, II Product Code: MKZ, LSL, O0I Dated: January 20, 2012 Received: January 23, 2012

Dear Mr. Bonds:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into class II (Special Controls), it may be subject to such additional controls.Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with al the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000- 1050. This letter will allow you to begin marketing your device as described in your Section $5 1 0 ( \mathbf { k } )$ premarket notification. The FDA finding of substantial equivalence of your device to a

Page 2 - James R. Bonds

legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and 809), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796- 5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to   
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address   
http://www.fda.gov/cdrh/industry/support/index.html.

.Sincerely yours,

![](images/7f302abe1f51cc08d0189af798a99ca16bc5c7d21b2801ec62771250ed19d16f.jpg)

Sally A. Hojvat, M.Sc., Ph.D.   
Director   
Division of Microbiology Devices   
Office of In Vitro Diagnostic Device   
Evaluation and Safety   
Center for Devices and Radiological Health

# cobas® CT/NG Test Indications for Use Statement

510(k) Number (if known): Device Name: Indications for Use:

K110923   
Roche cobas® CT/NG Test   
Assay

The cobas® CT/NG Test is an in vitro nucleic acid amplification test that utilizes Polymerase Chain Reaction (PCR) and nucleic acid hybridization for the qualitative detection of Chlamydia trachomatis (CT) and/or Neisseria gonorrhoeae (NG) DNA to aid in the diagnosis of chlamydial and gonococcal disease. The test may be used with vaginal swab specimens self-collected in a clinical setting and male urine from both symptomatic and asymptomatic individuals. Specimens to be tested should be collected in cobas® PCR Media.

# Ancillary Collection Kits

The cobas® PCR Female Swab Sample Kit is used to collect and transport self-collected vaginal swab specimens in a clinical setting. The coas CR Media serves as a nucleic acid stabilizing transport an storage medium for gynecological specimens. Use this collection kit only with the cobas® CT/NG Test. NOTE: This collection kit should not be used for collection of alternative gynecological specimens.

The cobas® PCR Urine Sample Kit is used to collect and transport male urine specimens.

The cobas PCR Media serves as a nucleic acid stabilizing transport and storage medium for urine specimens. Use this collection kit only with the cobas® CT/NG Test. NOTE: This collection kit should not be used for collection of female urine specimens.

Over-The-Counter Use (Per 21 CFR Subpart C)

Divislon Sign-Off

Office of In Vitro Dlagnostle DexineEyalHationrAss \$afety 510(k) K110923